# 2026年1月1日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 重症监护病房谵妄预防与管理干预的系统性元综述：第一部分——药物干预

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469920)
**期刊：** Critical care (London, England)
**PMID：** 41469920
**DOI：** 10.1186/s13054-025-05615-0

### 第一部分 原文与翻译

**英文原标题：** A systematic meta-review of interventions to prevent and manage delirium in the Intensive Care Unit: Part 1 - Pharmacological interventions.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究作为对重症监护病房谵妄预防与管理干预的系统性元综述，聚焦于药物相关措施，旨在综合现有证据，厘清药物干预的有效性与安全性。此类研究通过整合多层级综述，能够为临床决策提供更高层次的证据支撑。虽然目前摘要缺失，完整文本预期将揭示不同药物策略在谵妄防治中的比较效果与局限性。整体来看，该研究在方法学严谨性与证据整合深度方面具备较高学术价值。

---

## 2. 通过靶向 Shroom3-Rock 相互作用，为慢性肾病风险等位基因设计精准治疗药物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469391)
**期刊：** Nature communications
**PMID：** 41469391
**DOI：** 10.1038/s41467-025-67854-7

### 第一部分 原文与翻译

**英文原标题：** Design of precision therapeutics for a CKD risk allele by targeting Shroom3-Rock interaction.

> **英文摘要：**
> Enhancer variants in Shroom3 associate with renal fibrosis (TIF), but with reduced albuminuria. Detailed mechanisms for these pleiotropic effects are unclear. Here, we focus on identifying the specific profibrotic Shroom3 motif and separating this from its anti-proteinuric function. Given the role for Rho-kinases (Rock) in TIF, and the interaction of Rock with Shroom3 ASD2-domain, we hypothesized that Shroom3-mediated Rock-activation is crucial for profibrotic function. To test this, we develop transgenic tools that overexpress wild-type- (WT-Sh3) or ASD2-domain deletion- Shroom3 (ASD2Δ-Sh3). During TIF, Shroom3 and Rock co-expression occur in injured tubular cells and fibroblasts. In tubular- & fibroblast- lines, ASD2Δ-Sh3 overexpression reduce Rock activation, and pro-fibrotic/pro-inflammatory transcripts downstream of TGFβ1/Wnt/Ctnnb1-signaling vs WT-Sh3. In vivo, inducible global-, or tubular-specific-, but not fibroblast-specific-, ASD2Δ-Sh3 overexpression mitigate TIF, vs WT-Sh3 overexpression. Importantly, ASD2Δ-Sh3 mice do not develop albuminuria, while overexpression of a distinct Fyn-binding deficient mutant Shroom3 (FBDM-Sh3) induces albuminuria. We then develop small molecule inhibitors of Shroom3-Rock interaction (P2Is) and confirm Rock inhibition with these agents in WT-Sh3 cell lines. Our lead P2I from these studies, BT1137, mitigates Rock-activation, profibrotic signaling and TIF in WT-Sh3 mice. Hence, we delineate the profibrotic Shroom3 motif and develop therapeutics for kidney disease from Shroom3 excess.

> **中文摘要：**
> Shroom3 的增强子变异与肾纤维化（TIF）有关，但却伴随尿白蛋白减少。这些多效性作用的具体机制尚不明确。本研究旨在鉴定 Shroom3 中特异性的促纤维化结构域，并将其与抗蛋白尿功能区分开来。鉴于 Rho 激酶（Rock）在 TIF 中的作用，以及 Rock 与 Shroom3 ASD2 结构域的相互作用，我们假设 Shroom3 介导的 Rock 激活对于其促纤维化功能至关重要。为验证此假设，我们构建了过表达野生型（WT-Sh3）或 ASD2 结构域缺失型（ASD2Δ-Sh3）Shroom3 的转基因模型。在 TIF 过程中，Shroom3 与 Rock 在受损的肾小管上皮细胞和成纤维细胞中共表达。在肾小管与成纤维细胞系中，与 WT-Sh3 相比，ASD2Δ-Sh3 过表达可降低 Rock 的激活程度，并抑制 TGFβ1/Wnt/Ctnnb1 信号通路下游的促纤维化/促炎性转录物。在体内实验中，无论是诱导型全身性还是肾小管特异性的 ASD2Δ-Sh3 过表达，均可缓解 TIF，而成纤维细胞特异性过表达则无显著效果。重要的是，ASD2Δ-Sh3 小鼠并不会出现蛋白尿，而过表达另一种 Fyn 结合缺陷突变体 Shroom3（FBDM-Sh3）的小鼠则会产生蛋白尿。随后，我们开发了小分子 Shroom3-Rock 相互作用抑制剂（P2Is），并在 WT-Sh3 细胞系中验证了其对 Rock 的抑制作用。研究获得的先导化合物 BT1137 能够抑制 Rock 激活、阻断促纤维化信号并在 WT-Sh3 小鼠中减轻 TIF。因此，我们明确了 Shroom3 的促纤维化功能结构域，并基于 Shroom3 过表达开发出治疗肾病的精确药物。

### 第二部分 AI 大师评价

该研究围绕 Shroom3 与 Rock 相互作用在肾纤维化中的作用机制，系统解析了其致病与保护功能的分子基础。作者通过转基因小鼠模型和细胞实验相结合的方法，揭示了 ASD2 结构域在促进 Rock 活化及纤维化中的关键作用；并通过定向突变实验验证了不同结构域对蛋白尿等表型的影响。进一步开发的 Shroom3-Rock 抑制剂 BT1137 为慢性肾病治疗提供了潜在的新型精准药物。研究创新性在于将结构功能解析与小分子药物设计紧密结合，但仍需在临床可行性及靶向选择性方面进一步验证。

---

## 3. OASL的内在表达调控流感A病毒感染过程中干扰素诱导的细胞异质性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41468430)
**期刊：** Proceedings of the National Academy of Sciences of the United States of America
**PMID：** 41468430
**DOI：** 10.1073/pnas.2509560123

### 第一部分 原文与翻译

**英文原标题：** Intrinsic OASL expression governs heterogeneity in interferon induction during influenza A virus infection.

> **英文摘要：**
> Effective control of viral infection requires rapid induction of the innate immune response, especially the type I and type III interferon (IFN) systems. Despite the critical role of IFN induction in host defense, numerous studies have established that most cells fail to produce IFNs in response to viral stimuli. The specific factors that govern cellular heterogeneity in IFN induction potential during infection are not understood. To identify specific host factors that license some cells but not others to mount an IFN response to viral infection, we developed an approach for analyzing temporal scRNA-seq data of influenza A virus (IAV)-infected cells. This approach identified the expression of several interferon stimulated genes (ISGs) within preinfection cells as correlates of IFN induction potential of those cells, postinfection. Validation experiments confirmed that intrinsic expression of the ISG OASL is essential for robust IFNL induction during IAV infection. Altogether, our findings reveal an important role for intrinsic expression of ISGs in promoting IFN induction and provide insights into the mechanisms that regulate cell-to-cell heterogeneity in innate immune activation.

> **中文摘要：**
> 有效控制病毒感染需要迅速诱导先天免疫反应，尤其是I型和III型干扰素（IFN）系统。尽管干扰素诱导在宿主防御中起关键作用，但大量研究表明，大多数细胞在应对病毒刺激时并不产生干扰素。感染过程中决定细胞干扰素诱导潜能异质性的特定因素尚不清楚。为鉴定能够使部分细胞而非其他细胞在病毒感染中产生干扰素反应的特定宿主因子，我们开发了一种用于分析流感A病毒（IAV）感染细胞时间序列scRNA-seq数据的方法。该方法发现，感染前细胞中若干干扰素刺激基因（ISGs）的表达与其感染后干扰素诱导潜能相关。验证实验确认，ISG OASL的内在表达对于IAV感染期间强有力的IFNL诱导至关重要。总体而言，我们的研究结果揭示了ISG内在表达在促进干扰素诱导中的重要作用，并为调控先天免疫激活中细胞间异质性的机制提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在阐明为何同种细胞在病毒感染后诱导干扰素反应的能力存在显著差异。作者基于流感A病毒感染模型，利用时序单细胞RNA测序技术，揭示感染前内在表达的OASL等干扰素刺激基因是决定细胞干扰素诱导潜能的关键因素。结果表明，OASL的基础表达对于IFNL信号的强度具有决定性作用。研究创新性地将基因表达异质性与抗病毒反应能力直接相关联，为理解先天免疫系统的细胞层面调控机制提供了新的思路，但仍需进一步验证其在其他病毒感染模型中的普适性。

---

## 4. 表皮驻留记忆T细胞的适应性依赖于皮肤中的抗原遭遇。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41468295)
**期刊：** eLife
**PMID：** 41468295
**DOI：** 10.7554/eLife.107096

### 第一部分 原文与翻译

**英文原标题：** Epidermal resident memory T cell fitness requires antigen encounter in the skin.

> **英文摘要：**
> CD8 tissue-resident memory T cells (T) develop from effectors that seed peripheral tissues where they persist providing defense against subsequent challenges. T persistence requires autocrine TGFβ transactivated by integrins expressed on keratinocytes. T precursors that encounter antigen in the epidermis during development outcompete bystander T for TGFβ resulting in enhanced persistence. ScRNA-seq analysis of epidermal T revealed that local antigen experience in the skin resulted in an enhanced differentiation signature in comparison with bystanders. Upon recall, T displayed greater proliferation dictated by affinity of antigen experienced during epidermal development. Finally, local antigen experienced T differentially expressed TGFβRIII, which increases avidity of the TGFβRI/II receptor complex for TGFβ. Selective ablation of  reduced local antigen experienced T capacity to persist, rendering them phenotypically like bystander T. Thus, antigen-driven TCR signaling in the epidermis during T differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal T fitness.

> **中文摘要：**
> CD8型组织驻留记忆T细胞（T）由播散至外周组织的效应细胞分化而来，这些细胞在局部长期存留，为机体提供对后续致病攻击的防御。T细胞的持续存在依赖由角质形成细胞表达的整合素介导的自分泌TGFβ转活化。发育过程中在表皮中遭遇抗原的T细胞前体，会在TGFβ的竞争中胜过旁观T细胞，从而增强其持久性。表皮T细胞的单细胞RNA测序分析显示，相比于旁观细胞，皮肤局部的抗原经历可诱导更强的分化特征。再次暴露于抗原时，这些T细胞展示出更强的增殖能力，其程度受表皮发育期所经历抗原亲和力的调控。最后，经历局部抗原刺激的T细胞差异性表达TGFβRIII，该受体可提高TGFβRI/II受体复合物对TGFβ的亲合力。选择性敲除该受体会削弱局部抗原经历T细胞的持续存留能力，使其表型类似于旁观T细胞。因此，在表皮内分化期间，抗原驱动的TCR信号传导使得T细胞对TGFβ的依赖性降低、增殖能力增加，从而共同提升表皮驻留T细胞的适应性。

### 第二部分 AI 大师评价

本研究聚焦于CD8表皮驻留记忆T细胞的维持机制，揭示其适应性取决于发育过程中在皮肤内的抗原遭遇。研究者通过单细胞转录组分析和功能实验，发现局部抗原刺激可增强这些T细胞的分化特征和增殖潜能，并通过上调TGFβRIII强化TGFβ信号依赖。该研究创新性地阐明了抗原驱动的表皮微环境如何塑造驻留T细胞的长寿命与反应能力，为皮肤免疫记忆及疫苗设计提供了新理论基础。然而，其动物模型结果仍需在临床层面进一步验证。

---

## 5. 早产相关肺疾病从婴儿期至成年期的管理

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41319661)
**期刊：** The Lancet. Respiratory medicine
**PMID：** 41319661
**DOI：** 10.1016/S2213-2600(25)00369-8

### 第一部分 原文与翻译

**英文原标题：** Management of prematurity-associated lung disease from infancy through to adulthood.

> **英文摘要：**
> Preterm birth has lifelong pulmonary consequences, with many individuals developing prematurity-associated lung disease (PLD). This third paper in the prematurity-associated lung disease Series summarises current evidence for treatment and monitoring of PLD and its phenotypes. Preventive strategies, including maternal and infant vaccination to reduce early life viral exposures, are emerging as key interventions. Pharmacological approaches, such as inhaled corticosteroids, alone or combined with long-acting bronchodilators, show potential benefits in childhood, although there is currently little evidence on phenotype-specific responses. Management should also address extrapulmonary traits, including central airway abnormalities, cardiovascular sequelae, gastro-oesophageal reflux, impaired growth, neurodevelopmental disabilities, reduced physical exercise capacity, and environmental exposures. We discuss monitoring tools for early identification and longitudinal assessment of PLD, evaluation of treatment response, and recommendations for structured follow-up from infancy into adulthood, suitable for both general and specialist respiratory clinicians. Finally, opportunities for repurposing existing drugs and developing new therapies for PLD in children and adults are highlighted.

> **中文摘要：**
> 早产对肺的健康具有终生影响，许多个体会发展为早产相关肺疾病（PLD）。本系列关于早产相关肺疾病的第三篇文章总结了目前关于PLD及其表型的治疗与监测证据。预防策略方面，包括通过母体和婴儿接种疫苗以减少早期病毒暴露，正在成为关键的干预手段。药物治疗途径方面，如吸入性糖皮质激素单独或与长效支气管扩张剂联合使用，在儿童期显示出潜在的获益，尽管目前关于特定表型反应的证据仍然有限。管理PLD时还应关注肺外特征，包括中央气道异常、心血管后遗症、胃食管反流、生长受限、神经发育障碍、体能下降以及环境暴露等。本文讨论了用于早期识别和纵向评估PLD的监测工具、治疗反应的评估方法，并提出了从婴儿期至成年期的结构化随访建议，适用于普通及专科呼吸科医生。最后，文中强调了重新利用现有药物以及为儿童和成人开发新疗法的潜在机遇。

### 第二部分 AI 大师评价

本研究聚焦于从婴儿期到成年期的早产相关肺疾病的长期管理，系统总结了诊治与监测的最新证据。作者强调了预防策略的重要性，尤其是疫苗接种在减少早期病毒暴露中的作用；同时探讨了吸入性糖皮质激素与长效支气管扩张剂等药物治疗的潜力。文章还指出了管理中需整合肺外系统的共病因素，并提出系统随访和监测建议。该综述的创新性在于将PLD的全生命历程管理框架化，但目前表型特异性证据仍有限，是未来研究的重要方向。

---

## 6. 是时候利用人工智能破解疫苗与HLA关联问题了

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41265462)
**期刊：** The Lancet. Infectious diseases
**PMID：** 41265462
**DOI：** 10.1016/S1473-3099(25)00687-5

### 第一部分 原文与翻译

**英文原标题：** Time to tackle vaccine-HLA associations with artificial intelligence.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无提供。

### 第二部分 AI 大师评价

该论文标题指出了利用人工智能方法研究疫苗与人类白细胞抗原（HLA）系统之间关联的重要性。该研究领域有望揭示个体免疫反应差异的遗传基础，并推动个体化疫苗策略的发展。尽管目前缺少摘要，但标题暗示作者呼吁在高维遗传数据分析中引入AI，以应对传统方法难以处理的复杂性。其创新性在于融合免疫遗传学与人工智能的跨学科思路，局限性则可能在于数据异质性与可解释性挑战。

---

## 7. 用于神经保护的气体疗法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260719)
**期刊：** Critical care clinics
**PMID：** 41260719
**DOI：** 10.1016/j.ccc.2025.08.004

### 第一部分 原文与翻译

**英文原标题：** Gas Therapies for Neuro-Protection.

> **英文摘要：**
> Cardiac arrest (CA) remains a major cause of mortality and neurologic impairment, underscoring the urgent need for innovative neuroprotective strategies. Gas therapies, including inhaled nitric oxide (NO), molecular hydrogen (H), xenon (Xe), and argon (Ar), have emerged as promising neuroprotective agents. These gases exert protective effects, preserving neurologic function and improving outcomes after CA through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. Despite promising preclinical and early clinical data, large-scale trials are essential to validate their efficacy, optimize protocols, refine dosing, and ensure clinical translation. Advancing gas therapies into standard post-CA care could revolutionize neuroprotection, offering a paradigm shift in resuscitation medicine.

> **中文摘要：**
> 心脏骤停（CA）仍然是导致死亡和神经功能损伤的主要原因，这突显了对创新性神经保护策略的迫切需求。包括吸入一氧化氮（NO）、分子氢（H₂）、氙（Xe）和氩（Ar）在内的气体疗法，已成为具有前景的神经保护手段。这些气体通过抗氧化、抗炎及抗凋亡的机制发挥保护作用，从而维持神经功能并改善CA后的预后。尽管前临床和早期临床数据结果令人鼓舞，但仍需开展大规模试验以验证其疗效、优化治疗方案、细化剂量并确保临床可转化性。若将气体疗法推进为CA后的标准治疗措施，可能将彻底改变神经保护领域，为复苏医学带来范式转变。

### 第二部分 AI 大师评价

本文综述了多种潜在的气体疗法在心脏骤停后的神经保护作用，重点阐述了其抗氧化、抗炎及抗凋亡机制。该研究的核心目的是探索NO、H₂、Xe及Ar等气体的应用前景，并为临床转化提供方向。文章强调尽管前景可期，但仍需高质量的大规模临床试验证实疗效并优化治疗参数。其创新性在于整合不同气体的多机制神经保护证据，局限性则在于当前研究多为实验性阶段。

---

## 8. 院外心脏骤停体外心肺复苏的最新进展综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260717)
**期刊：** Critical care clinics
**PMID：** 41260717
**DOI：** 10.1016/j.ccc.2025.08.003

### 第一部分 原文与翻译

**英文原标题：** State-of-the-Art Update in Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest.

> **英文摘要：**
> Survival of refractory non-traumatic out-of-hospital cardiac arrest (OHCA) remains low despite many advances in care. Extracorporeal cardiopulmonary resuscitation (ECPR) has demonstrated the ability to significantly improve outcomes in select patients suffering refractory OHCA. These trials highlight different, but important, aspects of ECPR and provide insights into how we should design future ECPR systems of care. As the use of ECPR increases, this article updates the state-of-the-art in ECPR for refractory OHCA, highlighting the critical components of contemporary ECPR systems of care, clinical controversies in post-resuscitation strategies, and future areas of research needed.

> **中文摘要：**
> 尽管治疗手段已有诸多进展，但难治性非创伤性院外心脏骤停（OHCA）的生存率仍然较低。体外心肺复苏（ECPR）已显示可在部分难治性OHCA患者中显著改善预后。这些试验强调了ECPR的不同但关键的方面，并为未来ECPR救治体系的设计提供了重要见解。随着ECPR应用的增加，本文更新了关于难治性OHCA中ECPR的最新进展，重点阐述了当代ECPR救治体系的关键要素、复苏后治疗策略中的临床争议以及未来需要深入研究的领域。

### 第二部分 AI 大师评价

本文旨在综述院外心脏骤停中体外心肺复苏（ECPR）的最新发展，聚焦其在改善难治性病例预后方面的潜力。通过整合近期试验结果，作者总结了ECPR体系构建的核心组成部分及实施策略。文章还讨论了复苏后管理中的临床争议和现有证据的不足。其创新性在于系统梳理现行ECPR方案的关键环节，并为未来研究和体系优化提供方向。

---

## 9. 心搏骤停后康复门诊与多学科门诊随访

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260716)
**期刊：** Critical care clinics
**PMID：** 41260716
**DOI：** 10.1016/j.ccc.2025.08.013

### 第一部分 原文与翻译

**英文原标题：** Postcardiac Arrest Care Clinics and Multidisciplinary Outpatient Follow Up.

> **英文摘要：**
> Cardiac arrest survivorship is an evolving field focusing on long-term recovery, encompassing physical, cognitive, and psychological health. Despite increased survival rates, many survivors face challenges such as cognitive impairment, emotional distress, mobility issues, and caregiver burden. Current follow-up care has limited structured screening and multidisciplinary support. A pilot recovery program at a single center demonstrated high rates of cognitive impairment and readmissions, highlighting the need for comprehensive post-intensive care unit clinics, nurse navigation, and targeted interventions. Key research priorities include long-term outcome studies, rehabilitation strategies, telemedicine, caregiver support, and cost-effectiveness analyses to optimize survivor care and improve quality of life.

> **中文摘要：**
> 心搏骤停后的生存照护是一个不断发展的领域，重点关注包括身体、认知及心理健康在内的长期康复。虽然存活率有所提高，但许多幸存者仍面临认知障碍、情绪困扰、行动受限及照护者负担等挑战。当前的随访护理在结构化筛查和多学科支持方面仍然有限。单中心试点康复项目显示幸存者的认知障碍和再入院率较高，凸显了建立综合性重症监护后门诊、护理导航及针对性干预的必要性。主要研究重点包括长期结局研究、康复策略、远程医疗、照护者支持以及成本效益分析，以优化幸存者照护并改善生活质量。

### 第二部分 AI 大师评价

该研究综述了心搏骤停后患者长期康复照护的重要性与现有不足，提出建立多学科随访和综合管理模式的迫切需求。其核心在于通过试点项目揭示高认知障碍与再入院率，强调综合门诊与护理导航的价值。创新点在于引入系统化随访和跨专业协作理念，为未来康复策略和远程管理研究提供方向。局限在于目前证据多源自单中心试点，仍需多中心长期验证。

---

## 10. 急诊心血管救治中的实施挑战

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260715)
**期刊：** Critical care clinics
**PMID：** 41260715
**DOI：** 10.1016/j.ccc.2025.08.002

### 第一部分 原文与翻译

**英文原标题：** Implementation Challenges in Emergency Cardiovascular Care.

> **英文摘要：**
> Cardiac arrest is a significant public health issue, with high associated morbidity and mortality. However, it is a modifiable disease process, with a better chance of a good outcome when high-quality cardiopulmonary resuscitation is provided. Despite clear guidelines, gaps in translating these recommendations into practice remain prevalent. Effective implementation requires addressing these complex sociotechnical scenarios using comprehensive approaches informed by the principles of disciplines such as implementation science (IS). IS, which promotes the systematic uptake of evidence-based practices into routine practice, is well-suited for the challenges of implementation in emergency cardiovascular care and has been underutilized to date.

> **中文摘要：**
> 心脏骤停是一个重大的公共卫生问题，其相关的发病率和死亡率都很高。然而，这是一种可以干预的疾病过程，当提供高质量的心肺复苏时，获得良好结局的机会更大。尽管已有明确的指南，但将这些建议转化为临床实践的差距仍然普遍存在。有效的实施需要采用受实施科学（IS）等学科原则指导的综合方法，以应对这些复杂的社会技术情境。实施科学旨在促进循证实践系统地融入常规工作，对于应对急诊心血管救治的实施挑战极为适用，但迄今为止尚未得到充分利用。

### 第二部分 AI 大师评价

该研究聚焦于急诊心血管救治中循证指南的实施难题，指出心脏骤停虽是高风险事件，但可通过高质量心肺复苏改善预后。作者强调，将指南转化为实践的障碍主要源于复杂的社会技术因素，并提出应用实施科学的方法以优化落实过程。文章的创新在于将实施科学框架引入急诊心血管护理领域，为提升指南执行一致性提供理论支持。但该综述仍需进一步的实践验证和策略量化研究。

---

## 11. 阿片类药物流行时代的药物过量相关心脏骤停

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260714)
**期刊：** Critical care clinics
**PMID：** 41260714
**DOI：** 10.1016/j.ccc.2025.08.008

### 第一部分 原文与翻译

**英文原标题：** Overdose-Related Cardiac Arrest in the Era of the Opioid Epidemic.

> **英文摘要：**
> This article reviews the multifaceted landscape of overdose-associated out-of-hospital cardiac arrest in the context of the ongoing opioid epidemic and opioid-associated. It synthesizes current knowledge on epidemiology, pathophysiology, prehospital and hospital management, outcomes, and prevention strategies. The article emphasizes the clinical nuances of polysubstance overdoses, postarrest care, and highlights critical gaps in research, especially around naloxone use and postresuscitation care.

> **中文摘要：**
> 本文综述了在持续的阿片类药物流行背景下，与药物过量相关的院外心脏骤停的多层面特征。文中整合了当前关于流行病学、病理生理学、院前及院内处理、预后以及预防策略的研究进展。文章强调了多种物质联合过量及心脏骤停后护理的临床细节，并指出了研究中的关键空白，特别是在纳洛酮使用及复苏后护理方面的不足。

### 第二部分 AI 大师评价

本研究综述旨在系统阐述阿片类药物流行期间药物过量所致心脏骤停的流行病学特点及处理策略。作者综合现有证据，揭示了从院前处置到院内监护及随访管理的全流程挑战。文章的创新之处在于强调多药物过量病例的复杂性及复苏后护理的重要性，同时指出当前在纳洛酮应用和复苏后管理方面的研究空白，为未来研究方向提供了参考。

---

## 12. 无脉搏，无恐慌！左心室辅助装置支持患者心脏骤停的应对策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260712)
**期刊：** Critical care clinics
**PMID：** 41260712
**DOI：** 10.1016/j.ccc.2025.08.011

### 第一部分 原文与翻译

**英文原标题：** No Pulse, No Panic! Navigating Cardiac Arrest in LVAD-Supported Patients.

> **英文摘要：**
> The increasing use of left ventricular assist devices (LVADs) for advanced heart failure presents new challenges in emergency care, especially during cardiac arrest. LVAD-supported patients often lack palpable pulses and may have unreliable blood pressure readings, complicating diagnosis. Management strategies vary, with debates over whether to delay chest compressions to troubleshoot the device or initiate immediate resuscitation. Recognizing cardiac arrest involves alternative assessments like end-tidal co and ultrasound. Limited evidence and inconsistent guidelines highlight the need for standardized protocols, training, and large registries to improve outcomes and guide best practices for prehospital and hospital management of LVAD patients experiencing cardiac emergencies.

> **中文摘要：**
> 左心室辅助装置（LVAD）在重度心力衰竭患者中的日益广泛使用，为急救医学带来了新的挑战，尤其是在心脏骤停情况下。接受LVAD支持的患者常常缺乏可触及的脉搏，并可能出现血压读数不可靠的情况，从而使诊断更加复杂。管理策略存在差异，主要争论集中于应否延迟胸外按压以排查装置问题，还是立即启动心肺复苏。识别心脏骤停需借助替代性评估方法，如呼气末二氧化碳监测和超声检查。有限的证据与不一致的指南凸显了建立标准化操作流程、系统培训以及大型登记数据库的迫切需求，以改善预后并为LVAD患者院前及院内的心脏急症处理提供最佳实践指导。

### 第二部分 AI 大师评价

本文针对LVAD支持患者在心脏骤停时的独特急救挑战进行了系统性综述，强调了脉搏与血压测量的局限性及诊断复杂性。作者比较了延迟胸外按压与立即复苏的不同策略，并提出替代性评估方法的重要性。研究指出当前证据不足、指南不一致的现实问题，呼吁建立标准化管理流程与培训体系。整体上，该文为优化LVAD患者急救管理提供了重要启示，但仍需更多临床数据支持其具体建议。

---

## 13. 心脏骤停药物全书：心肺复苏期间个体化药物给应用途

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260710)
**期刊：** Critical care clinics
**PMID：** 41260710
**DOI：** 10.1016/j.ccc.2025.08.005

### 第一部分 原文与翻译

**英文原标题：** Cardiac Arrest Pharmacopeia: A Personalized Approach to Drug Administration During Cardiopulmonary Resuscitation.

> **英文摘要：**
> In this article, we describe the potential for personalized cardiopulmonary resuscitation using physiology to guide drug administration. We also highlight the limitations of the current evidence to inform a more individualized approach. Several areas for possible modifications to drug management are ripe for investigation, including: vasopressor selection and titration based on diastolic blood pressure responses; special physiologic circumstances in which sodium bicarbonate or calcium may be beneficial; and certain electrophysiologic states in shockable cardiac arrest, which may favor lidocaine or amiodarone.

> **中文摘要：**
> 本文描述了利用生理学指标指导药物给药，从而实现个体化心肺复苏的潜力。作者还强调了当前证据在指导更加个体化策略方面的局限性。多个药物管理可修改的领域值得深入研究，包括：基于舒张压反应的血管加压药选择与滴定；在特定生理条件下碳酸氢钠或钙可能具有的潜在益处；以及在可电击性心脏骤停中某些电生理状态下，利多卡因或胺碘酮的优先适用。

### 第二部分 AI 大师评价

本文聚焦于心肺复苏期间药物应用的个体化策略，提出以生理指标为基础指导给药的新思路。作者系统分析了当前证据的不足，并指出未来药物管理可能优化的关键环节，如血管加压药滴定与特定生理状态下辅助用药选择。该文的创新之处在于将个体化医学理念引入心肺复苏药物管理，但同时也强调现有研究尚不足以形成具体临床指南。总体而言，这是一篇具有重要启发意义的概念性综述。

---

## 14. 心肺复苏过程中通气的最新进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260709)
**期刊：** Critical care clinics
**PMID：** 41260709
**DOI：** 10.1016/j.ccc.2025.08.007

### 第一部分 原文与翻译

**英文原标题：** Advancements in Ventilation During Cardiac Resuscitation.

> **英文摘要：**
> Effective ventilation during cardiac arrest is vital for maintaining oxygenation and gas exchange, yet both hyperventilation and hypoventilation pose significant risks, including lung injury and neurologic damage. Current guidelines recommend specific ventilation volumes and rates, but evidence supporting these targets is limited, and actual practices often deviate, potentially impacting outcomes. Research challenges, such as the chaotic out-of-hospital setting, measurement inaccuracies, and patient heterogeneity, complicate the development of optimal strategies. Emerging technologies like real-time ventilation feedback devices and capnography offer promising avenues to improve ventilation quality, although their direct impact on survival and neurologic recovery remains unclear.

> **中文摘要：**
> 在心搏骤停过程中，有效的通气对于维持氧合和气体交换至关重要，然而过度通气和通气不足都带来显著风险，包括肺损伤和神经系统损害。当前指南建议采用特定的通气量与通气频率，但支持这些目标的证据有限，且实际操作常常发生偏离，可能影响预后。研究面临的挑战包括院外环境的混乱、测量误差以及患者异质性，这些因素使得优化通气策略的制定更加复杂。新兴技术，如实时通气反馈装置和二氧化碳监测，为提升通气质量提供了有希望的途径，尽管其对生存率和神经功能恢复的直接影响仍不明确。

### 第二部分 AI 大师评价

本研究聚焦于心肺复苏过程中通气管理的关键问题，综述了通气量与频率控制的重要性及其潜在风险。文章指出当前指南的依据有限，临床执行存在偏差，提示需要更高质量的证据支持。作者分析了研究中面临的现实困难，并探讨了实时反馈与监测技术在改善通气质量中的应用前景。其创新性体现在对新技术潜在价值的综合评估，但研究仍受限于缺乏对生存结局的直接验证。

---

## 15. 资源受限环境下的心脏骤停救治

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260708)
**期刊：** Critical care clinics
**PMID：** 41260708
**DOI：** 10.1016/j.ccc.2025.08.010

### 第一部分 原文与翻译

**英文原标题：** Cardiac Arrest Care in Resource-Limited Settings.

> **英文摘要：**
> Cardiac arrest care is a global problem, with high rates of morbidity and mortality. In resource-limited settings (RLS), survival is low for both in-hospital cardiac arrest and out-of-hospital cardiac arrest. Cardiac arrest care in RLS is limited by low rates of basic and advanced life support training, limited bystander cardiopulmonary resuscitation, nascent prehospital, emergency and critical care capacity and systems, limited human and material resources, and a paucity of data from RLS to inform guideline adaptation. Future steps to improve cardiac arrest care across the chain of survival include synergistic health systems strengthening, education, research, and legal and policy adaptations.

> **中文摘要：**
> 心脏骤停的救治是一个全球性问题，伴随着高发病率和高死亡率。在资源受限环境（RLS）中，无论是院内还是院外的心脏骤停，其生存率都较低。RLS 中心脏骤停救治受限于基础和高级生命支持培训率低、旁观者心肺复苏率有限、院前、急诊及重症救治能力和体系尚处于起步阶段、人力与物资资源匮乏，以及缺乏来自 RLS 的数据来指导指南的本地化调整。未来改进心脏骤停救治“生存链”的关键步骤包括协同强化卫生系统、加强教育与研究，并推进法律和政策的适应性改革。

### 第二部分 AI 大师评价

该研究聚焦于资源受限环境下的心脏骤停救治现状，强调其面临的体系性和资源性挑战。文章从培训、公众参与、急救体系建设以及政策支持等多层面分析了影响生存率的关键因素。作者提出需通过健康系统强化、教育与科研协同推动改革，为低资源地区提供实践导向的改进路径。该综述的价值在于整合多维度证据并提出结构化改进方向，但局限在于缺乏具体实施策略与实证数据支撑。

---

## 16. 生理学引导的心肺复苏

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41260707)
**期刊：** Critical care clinics
**PMID：** 41260707
**DOI：** 10.1016/j.ccc.2025.08.001

### 第一部分 原文与翻译

**英文原标题：** Physiology-Guided CPR.

> **英文摘要：**
> Current cardiopulmonary resuscitation (CPR) guidelines rely on standardized metrics, yet substantial evidence reveals significant variability in patients' physiologic responses. Physiology-directed CPR represents an innovative approach aimed at improving cardiac arrest outcomes by tailoring resuscitation efforts to patient-specific physiologic responses rather than rescuer performance alone. Data indicate that intra-arrest markers including arterial blood pressure, end-tidal carbon dioxide, and cerebral oximetry are associated with cardiac arrest outcomes and can potentially be targeted during CPR. This article explores the underlying physiology, supporting data, advantages, and limitations of these monitoring strategies, highlighting the promise of a shift toward physiology-directed, precision-based resuscitation practices.

> **中文摘要：**
> 当前的心肺复苏（CPR）指南依赖于标准化的指标，但大量证据表明患者的生理反应存在显著差异。生理学导向的 CPR 代表了一种创新方法，旨在通过根据患者特异性的生理反应而非仅仅依靠施救者的表现来调整复苏措施，从而改善心脏骤停的预后。研究数据显示，在心脏骤停期间的指标（包括动脉血压、呼气末二氧化碳分压和脑氧饱和度）与心脏骤停的结局相关，并可能成为 CPR 过程中可调控的目标。本篇文章探讨了这些监测策略的基础生理机制、支撑数据、优势和局限性，并强调了向生理学导向、精准复苏实践转变的潜力。

### 第二部分 AI 大师评价

本文旨在介绍基于患者个体生理反应调整的生理学导向心肺复苏理念，突破传统以统一操作指标为中心的模式。作者综合了血压、呼气末二氧化碳及脑氧监测等关键参数的相关证据，阐述其在预测与改善复苏结局中的意义。文章的创新在于强调个体化、实时调控的精准复苏思路，但同时面临监测技术普及、实时数据解释及操作标准化的挑战。

---

## 17. 胸外科单肺通气期间较高与较低呼气末正压对术后肺部并发症的影响（PROTHOR 研究）：一项多中心、国际、随机、对照的Ⅲ期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41240959)
**期刊：** The Lancet. Respiratory medicine
**PMID：** 41240959
**DOI：** 10.1016/S2213-2600(25)00330-3

### 第一部分 原文与翻译

**英文原标题：** Effects of intraoperative higher versus lower positive end-expiratory pressure during one-lung ventilation for thoracic surgery on postoperative pulmonary complications (PROTHOR): a multicentre, international, randomised, controlled, phase 3 trial.

> **英文摘要：**
> BACKGROUND: The effect of higher positive end-expiratory pressure (PEEP) and recruitment manoeuvres aimed at lung expansion as compared with lower PEEP without recruitment manoeuvres aimed at permissive atelectasis on postoperative pulmonary complications (PPCs) in patients undergoing one-lung ventilation (OLV) during thoracic surgery is unclear. We aimed to determine the contribution of an intraoperative lung expansion strategy to preventing PPCs.
> 
> METHODS: In this multicentre, randomised, controlled, international phase 3 trial (PROTHOR) conducted at 74 sites in 28 countries, we enrolled adult patients (aged ≥18 years) with a BMI of less than 35 kg/m who were scheduled for open thoracic or video-assisted thoracoscopic surgery under general anaesthesia requiring one-lung ventilation with a double-lumen tube, with a planned operative time of more than 60 min, and an expected duration of one-lung ventilation longer than that of two-lung ventilation. Patients were randomly assigned (1:1), using permuted blocks of random size (4, 6, and 8) and stratified by study site, to receive one-lung ventilation with either a higher PEEP of 10 cm HO and periodic lung recruitment manoeuvres (high PEEP group) or a lower PEEP of 5 cm HO without routine recruitment manoeuvres (low PEEP group). All patients received protective tidal volumes of 5 mL/kg predicted body weight during one-lung ventilation and 7 mL/kg predicted body weight during two-lung ventilation. Postoperative assessors were masked to treatment allocation. The primary outcome was a composite of PPCs during the first 5 postoperative days, including aspiration pneumonia, moderate or severe respiratory failure, acute respiratory distress syndrome (ARDS), pulmonary infection, atelectasis, cardiopulmonary oedema, pleural effusion, non-operative pneumothorax, pulmonary infiltrates, prolonged air leak, purulent pleuritis, pulmonary embolism, and pulmonary haemorrhage. A modified intention-to-treat analysis was performed, with patients analysed according to their assigned treatment group, except in cases of withdrawal of informed consent, cancellation of surgery, and or loss to follow-up. This trial is registered with ClinicalTrials.gov (NCT02963025) and is completed.
> 
> FINDINGS: Between Jan 3, 2017, and Feb 12, 2024, 2200 patients were randomly allocated: 1099 to the high PEEP group and 1101 to the low PEEP group. 43 patients in the high PEEP group and 33 in the low PEEP group were excluded from the modified intention-to-treat analysis after randomisation. The primary outcome occurred in 555 (53·6%) of 1036 patients in the high PEEP group and 592 (56·4%) of 1049 patients in the low PEEP group (absolute risk difference -2·68 percentage points [95% CI -6·36 to 1·01]; p=0·155). Intraoperative complications occurred in 484 (49·8%) of 972 patients in the high PEEP group and in 305 (31·3%) of 974 patients in the low PEEP group (absolute risk difference 18·09 percentage points [95% CI 14·41-21·77]), among which hypotension (360 [37·3%] of 966 patients in the high PEEP group vs 140 [14·3%] of 978 in the low PEEP group) and new arrhythmias (89 [9·9%] of 899 vs 37 [3·9%] of 956) were more frequent in the high PEEP group, while hypoxaemia rescue manoeuvres were more frequent in the low PEEP group (29 [3·3%] of 888 vs 86 [8·8%] of 982). The proportions of patients with extrapulmonary postoperative complications (110 [10·6%] of 1036 vs 107 [10·2%] of 1049 patients), and the numbers of adverse events (209 vs 204 events), did not differ between groups.
> 
> INTERPRETATION: In patients with a BMI of less than 35 kg/m undergoing thoracic surgery, one-lung ventilation using higher PEEP with recruitment manoeuvres, compared with lower PEEP without recruitment manoeuvres, did not reduce PPCs. The choice for intraoperative lung expansion or permissive atelectasis should take the individual gas-exchange and haemodynamic conditions into account, which might vary during the intraoperative period.
> 
> FUNDING: Clinical Trials Network of the European Society of Anaesthesiology and Intensive Care; Department of Anaesthesiology and Intensive Care, University Hospital Carl Gustav Carus, Technische Universität Dresden (Dresden, Germany); Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brasília, Brazil); and the Association of Anaesthetists of GB and Ireland.

> **中文摘要：**
> 背景：对于接受胸外科单肺通气（OLV）的患者而言，较高呼气末正压（PEEP）结合肺扩张手法，与较低 PEEP 且不进行肺复张、允许性肺不张相比，其对术后肺部并发症（PPCs）的影响尚不明确。本研究旨在确定术中肺扩张策略对预防术后肺部并发症的作用。
> 
> 方法：本项名为 PROTHOR 的多中心、随机、对照、国际Ⅲ期临床试验在28个国家的74个中心开展。纳入年龄≥18岁、体质指数（BMI）<35 kg/m²、计划接受全身麻醉下开胸或胸腔镜胸外科手术且需双腔管单肺通气的成年患者，预期手术时间>60分钟，且单肺通气时间预计长于双肺通气时间。患者按1:1比例随机分配至高 PEEP 组（PEEP 设为10 cmH₂O，并定期进行肺复张）或低 PEEP 组（PEEP 设为5 cmH₂O且不常规进行复张手法）。随机化采用不同区块大小（4、6、8）的置换区块法，并按研究中心分层。所有患者在单肺通气期间接受预测体重5 mL/kg 的保护性潮气量，在双肺通气期间接受7 mL/kg 的潮气量。术后评估者对分组情况保持盲法。主要终点为术后5天内发生的PPCs复合结局，包括吸入性肺炎、中度或重度呼吸衰竭、急性呼吸窘迫综合征（ARDS）、肺部感染、肺不张、心肺水肿、胸腔积液、非手术性气胸、肺部浸润、持续气漏、化脓性胸膜炎、肺栓塞和肺出血。采用改良意向性分析（mITT），除去撤回知情同意、手术取消及失访的病例。该试验已完成并注册于ClinicalTrials.gov（NCT02963025）。
> 
> 结果：2017年1月3日至2024年2月12日，共2200例患者被随机分配，高 PEEP 组1099例，低 PEEP 组1101例。随机后高 PEEP 组43例、低 PEEP 组33例被排除出mITT分析。主要终点在高 PEEP 组1036例患者中出现555例（53.6%），低 PEEP 组1049例患者中出现592例（56.4%）（绝对风险差 -2.68个百分点 [95% CI -6.36 至 1.01]；p=0.155）。术中并发症在高 PEEP 组（972例，49.8%）发生率高于低 PEEP 组（974例，31.3%）（绝对风险差18.09个百分点 [95% CI 14.41–21.77]），其中低血压（37.3% vs 14.3%）及新发心律失常（9.9% vs 3.9%）在高 PEEP 组更常见，而低氧救治操作在低 PEEP 组更常见（3.3% vs 8.8%）。两组在术后肺外并发症比例（10.6% vs 10.2%）及不良事件（209 vs 204 例）方面无明显差异。
> 
> 解释：对于BMI<35 kg/m²的胸外科患者，与低 PEEP 无复张策略相比，采用较高 PEEP 并结合复张手法的单肺通气并未降低术后肺部并发症。术中是否采取肺扩张或允许性肺不张策略，应综合考虑患者的气体交换及血流动力学状态，这些情况可能在术中持续变化。
> 
> 资金支持：欧洲麻醉与重症医学学会临床试验网络；德国德累斯顿工业大学卡尔·古斯塔夫·卡鲁斯大学医院麻醉与重症医学科；巴西国家科研发展委员会（CNPq）；英国与爱尔兰麻醉医师协会。

### 第二部分 AI 大师评价

该研究为一项大规模、多国多中心的Ⅲ期随机对照试验，系统比较了胸外科单肺通气期间不同呼气末正压水平和肺复张策略对术后肺部并发症的影响。结果显示，高PEEP联合复张策略并未减少肺部并发症，反而增加了低血压和心律失常等术中事件。研究强调个体化平衡气体交换与血流动力学的重要性。尽管结果否定了高PEEP的普遍优势，但为临床选择肺保护策略提供了坚实的循证依据。

---

## 18. 手术期间的通气策略：突破“一刀切”模式

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41240957)
**期刊：** The Lancet. Respiratory medicine
**PMID：** 41240957
**DOI：** 10.1016/S2213-2600(25)00364-9

### 第一部分 原文与翻译

**英文原标题：** Ventilation during surgery: moving away from one-size-fits-all.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文发表在《柳叶刀·呼吸医学》期刊，聚焦于围术期机械通气策略的个体化转变。标题暗示作者呼吁摒弃传统统一通气方案，提倡根据患者病理状态、术式及风险因素优化呼吸参数。尽管暂无摘要可供深入分析，但推测该文章可能总结最新临床证据并提出精准呼吸管理的未来方向。这种视角体现了从经验医学到精准医学的过渡，但具体实施仍需更多循证支持。

---

## 19. 基于移植后生存预测算法的供体肾脏质量评估研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41135690)
**期刊：** American journal of kidney diseases : the official journal of the National Kidney Foundation
**PMID：** 41135690
**DOI：** 10.1053/j.ajkd.2025.07.016

### 第一部分 原文与翻译

**英文原标题：** Assessing Deceased-Donor Kidneys Through Posttransplant Survival Prediction Algorithms.

> **英文摘要：**
> RATIONALE & OBJECTIVE: The Kidney Donor Risk Index (KDRI) is widely used to rank the quality of deceased-donor kidneys and is integrated into the U.S. kidney allograft allocation system. However, the KDRI has modest predictive accuracy for allograft survival, and recent revisions to the KDRI, which removed donor race and hepatitis C virus status, also revealed model calibration problems. This study aimed to evaluate novel approaches for predicting posttransplant allograft survival.
> 
> STUDY DESIGN: Retrospective cohort study using Organ Procurement and Transplantation Network data from May 1, 2007, through December 31, 2021.
> 
> PREDICTORS: (1) Donor demographic and clinical variables (established predictors); (2) longitudinal laboratory data from the donor's terminal hospitalization, such as serum creatinine (new predictors); and (3) recipient clinical variables (new predictors).
> 
> SETTING & PARTICIPANTS: 75,867 adult kidney recipients at U.S.
> 
> OUTCOMES: The primary outcome was time to all-cause allograft failure over 3 years. A secondary outcome was delayed graft function, defined as dialysis in the first week after the transplant.
> 
> ANALYTICAL APPROACH: We implemented and compared machine-learning statistical models versus traditional modeling approaches (ie, proportional hazards for the primary outcome and logistic regression of the secondary outcome) that incorporated various combinations of predictors. The performance metrics used to assess discrimination were the integrated (time-dependent) area under the curve (AUC) for allograft survival and the AUC for delayed graft function. To assess calibration, we calculated Brier scores and visually compared the predicted outcomes with the observed ones. Predictive performance was assessed in a 20% testing data split.
> 
> RESULTS: Neither machine-learning models nor the addition of longitudinal laboratory data from the donor hospitalization to traditional models improved discrimination. For the primary outcome, the final model (named the Kidney Allograft Survival Index) used a proportional hazards modeling approach. Adding recipient variables improved model discrimination (integrated AUC, 0.68) and achieved excellent calibration for the overall cohort and subgroups. The final model for delayed allograft function used logistic regression, included recipient variables, and had an AUC of 0.75 with acceptable calibration.
> 
> LIMITATIONS: No external validation.
> 
> CONCLUSIONS: Improving the discrimination and calibration of kidney allograft survival prediction models is achievable by including recipient characteristics. These enhanced models have potential to improve the system of kidney allocation.

> **中文摘要：**
> 研究背景与目的：肾脏供体风险指数（Kidney Donor Risk Index，KDRI）被广泛用于评估尸体供体肾脏的质量，并已纳入美国肾移植物分配体系。然而，KDRI 对移植物生存的预测准确性有限，且近期去除了供体种族和丙型肝炎病毒状态变量的修订版，也暴露出模型校准问题。本研究旨在评估预测移植后肾移植物生存的新方法。
> 
> 研究设计：回顾性队列研究，使用 2007 年 5 月 1 日至 2021 年 12 月 31 日期间的器官获取与移植网络数据。
> 
> 预测因子：（1）供体人口学和临床变量（既有预测因子）；（2）供体末期住院期间的纵向实验室数据，如血清肌酐（新预测因子）；以及（3）受者临床变量（新预测因子）。
> 
> 研究场景与参与者：美国的 75,867 名成年肾移植受者。
> 
> 研究结局：主要结局为 3 年内移植物全因失效率时间；次要结局为延迟移植物功能，定义为移植后第一周内需进行透析。
> 
> 分析方法：研究采用并比较了机器学习统计模型和传统统计建模方法（主要结局使用比例风险模型，次要结局使用逻辑回归），结合不同的预测因子组合。模型判别性能通过综合（时间依赖）曲线下面积（AUC）评估移植物生存预测能力，延迟移植物功能的预测能力同样以 AUC 衡量。校准性能通过 Brier 分数计算及预测结果与观测结果的可视化对比评估。预测性能在 20% 的测试数据集中进行检验。
> 
> 结果：无论是机器学习模型，还是将供体住院期间的纵向实验室数据添加至传统模型，均未提高模型判别力。针对主要结局的最终模型（命名为肾移植物生存指数，Kidney Allograft Survival Index）采用比例风险模型方案。加入受者变量后，模型判别力提升（综合 AUC 为 0.68），并在总体队列及亚组中实现了良好的校准。针对延迟移植物功能的最终模型采用逻辑回归，纳入受者变量后 AUC 为 0.75，校准性能可接受。
> 
> 研究局限性：缺乏外部验证。
> 
> 结论：通过将受者特征纳入预测，可改进肾移植物生存模型的判别力和校准性能。此优化模型有望提升肾脏分配体系的精确性。

### 第二部分 AI 大师评价

该研究针对现有肾脏供体风险指数（KDRI）预测性能有限的问题，利用美国大型移植数据库开展回顾性分析，比较了机器学习与传统统计模型在预测移植物生存方面的表现。结果发现，增加纵向供体实验室数据未能改善模型判别力，而加入受者临床变量后，模型的准确性与校准显著提高。研究提出了新的肾移植物生存指数（Kidney Allograft Survival Index），为肾脏分配优化提供了新思路。尽管缺乏外部验证，其方法学上对预测模型改良的探索具有创新性与实用价值。

---

## 20. Sacituzumab Tirumotecan 在EGFR-TKI耐药、突变型晚期非小细胞肺癌中的应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41124220)
**期刊：** The New England journal of medicine
**PMID：** 41124220
**DOI：** 10.1056/NEJMoa2512071

### 第一部分 原文与翻译

**英文原标题：** Sacituzumab Tirumotecan in EGFR-TKI-Resistant, -Mutated Advanced NSCLC.

> **英文摘要：**
> BACKGROUND: Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with -mutated non-small-cell lung cancer (NSCLC) that has progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy.
> 
> METHODS: In this phase 3 trial, we enrolled patients with -mutated locally advanced or metastatic nonsquamous NSCLC that had progressed after EGFR-TKI therapy. The patients were randomly assigned, in a 1:1 ratio, to receive sac-TMT monotherapy or pemetrexed plus platinum-based chemotherapy. The primary end point was progression-free survival as assessed by blinded independent review. Overall survival was a hierarchically tested key secondary end point. In the interim analysis of progression-free survival as assessed by blinded independent review, sac-TMT monotherapy met the prespecified criterion for significance (two-sided P<0.0001); we report here the prespecified final analysis of progression-free survival and the preplanned interim analysis of overall survival.
> 
> RESULTS: Overall, 376 patients underwent randomization, with 188 assigned to each group. After a median follow-up of 18.9 months, the median progression-free survival was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio for disease progression or death, 0.49; 95% confidence interval [CI], 0.39 to 0.62). Overall survival was significantly longer with sac-TMT than with chemotherapy (hazard ratio for death, 0.60; 95% CI, 0.44 to 0.82; two-sided P = 0.001); 18-month overall survival was 65.8% and 48.0%, respectively. Treatment-related adverse events of grade 3 or higher occurred in 58.0% of patients receiving sac-TMT and in 53.8% of those receiving chemotherapy, with the most common being a decreased neutrophil count (39.9% vs. 33.0%); treatment-related serious adverse events occurred in 9.0% and 17.6%, respectively.
> 
> CONCLUSIONS: In patients with -mutated advanced or metastatic NSCLC that had progressed after previous EGFR-TKI therapy, progression-free survival and overall survival outcomes were significantly better with sac-TMT than with platinum-based chemotherapy. (Funded by Sichuan Kelun-Biotech Biopharmaceutical; OptiTROP-Lung04 ClinicalTrials.gov number, NCT05870319.).

> **中文摘要：**
> 背景：Sacituzumab tirumotecan（sac-TMT）是一种针对滋养层细胞表面抗原2的抗体偶联药物，在表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗及含铂化疗后疾病进展的突变型非小细胞肺癌（NSCLC）患者中显示出显著的生存获益。
> 
> 方法：在这项Ⅲ期试验中，我们纳入了EGFR突变、局部晚期或转移性非鳞状NSCLC且在EGFR-TKI治疗后发生进展的患者。患者按照1:1比例随机分配，接受sac-TMT单药治疗或培美曲塞联合含铂化疗。主要终点为经盲法独立评审确定的无进展生存期。总生存期为分层检验的关键次要终点。在经盲法独立评审的无进展生存期中期分析中，sac-TMT单药治疗达到预先设定的显著性标准（双侧P<0.0001）；本文报告预设的无进展生存期最终分析及总生存期的预定中期分析结果。
> 
> 结果：共随机分配376名患者，每组188人。经过中位18.9个月的随访后，sac-TMT组的中位无进展生存期为8.3个月，化疗组为4.3个月（疾病进展或死亡的风险比为0.49；95%置信区间[CI]，0.39–0.62）。与化疗组相比，sac-TMT组的总生存期显著延长（死亡风险比为0.60；95% CI，0.44–0.82；双侧P=0.001）；18个月总生存率分别为65.8%和48.0%。与治疗相关的≥3级不良事件在sac-TMT组中发生率为58.0%，化疗组为53.8%，最常见的不良事件为中性粒细胞减少（39.9% vs. 33.0%）；与治疗相关的严重不良事件发生率分别为9.0%和17.6%。
> 
> 结论：在经既往EGFR-TKI治疗后出现进展的EGFR突变型晚期或转移性NSCLC患者中，sac-TMT较含铂化疗显著改善了无进展生存期和总生存期。（由四川科伦博泰生物制药公司资助；OptiTROP-Lung04 临床试验注册号 NCT05870319。）

### 第二部分 AI 大师评价

该研究是一项针对EGFR-TKI耐药的突变型晚期非小细胞肺癌的Ⅲ期随机对照试验，评估了抗体药物偶联物sacituzumab tirumotecan相较含铂化疗的疗效与安全性。结果显示，sac-TMT不仅显著延长了无进展生存期和总生存期，还在一定程度上降低了严重不良事件的发生率。研究为EGFR-TKI治疗失败后的患者提供了新的有效治疗选择。其创新性在于首次验证该新型ADC在EGFR突变肺癌中的临床优势，但长期疗效及后续耐药机制仍需进一步研究。

---

## 21. 流感疫苗接种与急性肾损伤关联性：一项前瞻性目标试验模拟研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41110628)
**期刊：** American journal of kidney diseases : the official journal of the National Kidney Foundation
**PMID：** 41110628
**DOI：** 10.1053/j.ajkd.2025.09.005

### 第一部分 原文与翻译

**英文原标题：** Association of Influenza Vaccination With Acute Kidney Injury: A Prospective Target Trial Emulation Study.

> **英文摘要：**
> RATIONALE & OBJECTIVE: The impact of influenza vaccination on the risk of acute kidney injury (AKI) has not been thoroughly evaluated in large-scale prospective studies. We assessed whether influenza vaccination was associated with a reduced incidence of AKI among individuals aged 65 years or older.
> 
> STUDY DESIGN: Target trial emulated with a sequential trial design.
> 
> SETTING & PARTICIPANTS: Participants aged 65 years or older in the UK Biobank.
> 
> EXPOSURE: Influenza vaccination compared with no influenza vaccine.
> 
> OUTCOME: Incident AKI during 1 year after vaccination. Participants were followed from baseline until the diagnosis of AKI, death, loss to follow-up, or for 1 year after entering the study, whichever occurred first.
> 
> ANALYTICAL APPROACH: Fifty trials were emulated, each with a 1-month enrollment period. These trials began in September 2007 and continued from September to January of the following year until January 2017. Eligible participants could be included in multiple trials until they no longer met the inclusion criteria. Propensity score matching was applied to match vaccine recipients to unvaccinated individuals in a 1:1 ratio to control for confounders, emulating random assignment. A clustered marginal competing risk model that accounts for the within-pair clustering of outcomes was fit to estimate the hazard ratio, along with the 95% confidence interval, characterizing the association between the use of influenza vaccination and incident AKI.
> 
> RESULTS: Overall, the cohort included 1,408,922 eligible person-trials in the general practice data. After propensity score matching, 97,663 pairs of person-trials were included. During the 1-year follow-up, a total of 598 incident AKI events were observed. In the primary analysis, the incidence of AKI was 36.8 per 10,000 person-years (PYs) in unvaccinated participants and 30.6 per 10,000 PYs in the vaccinated group. After adjusting for potential confounders using propensity score matching, influenza vaccination was associated with a 17% lower AKI risk (HR, 0.83 [95% CI, 0.71-0.98]). The cumulative mortality rates were 62.8 per 10,000 PYs in the unvaccinated group and 47.2 per 10,000 PYs in the vaccinated group, corresponding to an HR of 0.75 (95% CI, 0.66-0.85). These findings remained consistent in subgroup and sensitivity analyses.
> 
> LIMITATIONS: Potential residual confounding from variations in vaccine formulations and batch; potential selection bias from restricting to participants with linked primary care data in the UK Biobank; and potential outcome misclassification from use of a code-based algorithm to identify AKI.
> 
> CONCLUSIONS: In this prospective population-based study of older adults within the UK Biobank, influenza vaccination was significantly associated with a lower risk of incident AKI. These findings support use of influenza vaccination in older adults to reduce influenza and its kidney-related complications.
> 
> PLAIN-LANGUAGE SUMMARY: Influenza infection can damage multiple systems beyond the respiratory system and cause impairment of kidney function. We hypothesized that influenza vaccination may provide a more extensive protective effect beyond respiratory diseases. However, the impact of influenza vaccination on the risk of acute kidney injury (AKI) has not been sufficiently evaluated. This study investigated the association between influenza vaccination and AKI in older adults represented in the UK Biobank, a large prospective cohort. By emulating a targeted randomized clinical trial in this cohort, we found that influenza vaccination may reduce the risk of AKI by 17%. This effect was partially mediated by a reduction in influenza and pneumonia. These findings support the broader implementation of influenza vaccination to reduce both influenza and kidney-related complications in older adult populations.

> **中文摘要：**
> 研究动机与目的：流感疫苗接种对急性肾损伤（AKI）风险的影响尚未在大规模前瞻性研究中得到充分评估。本研究评估了流感疫苗接种是否与65岁及以上人群中AKI发病率降低相关。
> 
> 研究设计：采用顺序试验设计的目标试验模拟。
> 
> 研究环境与参与者：来自英国生物样本库（UK Biobank）的65岁及以上参与者。
> 
> 暴露因素：流感疫苗接种与未接种流感疫苗的比较。
> 
> 结局指标：接种后1年内新发AKI事件。参与者自基线起随访，直至出现AKI诊断、死亡、失访或进入研究1年，以先发生者为终点。
> 
> 分析方法：模拟了50项试验，每项试验的入组期为1个月。试验自2007年9月开始，每年9月至次年1月持续至2017年1月。符合条件的参与者可重复入组，直至不再满足纳入标准。采用倾向评分匹配，以1:1比例匹配接种者与未接种者，以控制混杂因素并模拟随机分配。采用考虑配对内结局聚类的分层边际竞争风险模型估计危险比及其95%置信区间，以描述流感疫苗接种与AKI发生的关联。
> 
> 结果：总体而言，队列包括1,408,922个符合条件的人次试验。倾向评分匹配后，共纳入97,663对人次试验。在1年随访期间，共观察到598例新发AKI事件。主要分析中，未接种者的AKI发生率为每10,000人年36.8例，接种者为30.6例。经倾向评分匹配调整混杂因素后，流感疫苗接种与17%较低的AKI风险相关（HR=0.83，95% CI 0.71–0.98）。累计死亡率在未接种组为每10,000人年62.8例，而接种组为47.2例，对应HR为0.75（95% CI 0.66–0.85）。亚组分析和敏感性分析结果一致。
> 
> 研究局限性：疫苗配方和批次差异可能导致残余混杂；仅限具有英国生物样本库初级保健关联数据的个体可能存在选择偏倚；基于编码算法识别AKI可能导致结局误分类。
> 
> 结论：在英国生物样本库老年人群的这项前瞻性人群研究中，流感疫苗接种与较低的新发AKI风险显著相关。这些结果支持在老年人中推广流感疫苗接种，以减少流感及其相关的肾脏并发症。
> 
> 通俗摘要：流感感染可损害除呼吸系统外的多系统功能，并导致肾功能障碍。我们假设流感疫苗可能在呼吸系统疾病之外提供更广泛的保护。然而，流感疫苗对急性肾损伤风险的影响尚未充分研究。本研究利用英国生物样本库这一大型前瞻性队列，探讨流感疫苗接种与AKI风险的关联。通过在该队列中模拟目标随机临床试验，我们发现流感疫苗接种可使AKI风险降低约17%。这一效应部分由流感及肺炎发病减少所介导。这些发现支持更广泛推广流感疫苗，以减少老年人群中的呼吸及肾脏相关并发症。

### 第二部分 AI 大师评价

本研究以英国生物样本库老年人群为基础，通过目标试验模拟法，探讨流感疫苗接种与急性肾损伤风险之间的关联。研究在设计上创新性地采用倾向评分匹配与竞争风险模型，模拟随机分配效果。结果显示，流感疫苗接种者的AKI风险降低约17%，提示疫苗可能具有超越呼吸系统的系统保护效应。尽管存在残余混杂与选择偏倚等局限，该研究为支持老年人接种流感疫苗提供了新的循证依据。

---

## 22. 药物诱导的深度镇静和机械通气期间情绪困扰与失去独立生活能力之间的关联：一项观察性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41086817)
**期刊：** The Lancet. Respiratory medicine
**PMID：** 41086817
**DOI：** 10.1016/S2213-2600(25)00264-4

### 第一部分 原文与翻译

**英文原标题：** Association of medication-induced deep sedation and emotional distress during mechanical ventilation with loss of independent living: an observational cohort study.

> **英文摘要：**
> BACKGROUND: Deep sedation can be used during invasive mechanical ventilation without proven indication to treat the signs and symptoms of emotional distress or insomnia. However, medication-induced deep sedation is associated with delayed recovery and increased mortality. We tested the hypothesis that medication-induced deep sedation, but not emotional distress, is associated with loss of independent living.
> 
> METHODS: In this retrospective cohort study, we included adult patients (age ≥18 years) who lived independently before hospital admission and were mechanically ventilated for at least 24 h in any of 20 ICUs at an academic health system in the Bronx, New York (NY, USA), and adjacent counties. The primary exposure was the proportion of time spent in medication-induced deep sedation (defined as a Richmond Agitation Sedation Score of -3 to -5) within the first week of ICU admission. The secondary exposure was the proportion of time with indicators of emotional distress within the first week of ICU admission. The exposures were categorised as none, a low proportion, or a high proportion using the median (42·9% for medication-induced deep sedation and 10·7% for emotional distress) as the cutoff between low and high. The primary outcome was loss of independent living (defined as in-hospital death or postoperative discharge to a long-term skilled nursing facility). Modified Poisson regression with an a priori-defined confounder control model were used to assess the association between exposures and outcomes. Mediation analysis was done to evaluate whether patient mobilisation level during mechanical ventilation contributed to the association between deep sedation and loss of independent living.
> 
> FINDINGS: Among 10 204 patients receiving invasive mechanical ventilation between Jan 30, 2016 and July 11, 2023, 6369 (62·4%) had a loss of independent living. The proportion of patients who received deep sedation was a mean 2·84-fold (SD 1·51) higher than the proportion of patients who had an order for deep sedation. 7289 (71·4%) patients had at least one episode of medication-induced deep sedation within the first week of mechanical ventilation in the ICU. A high proportion of medication-induced deep sedation was associated with an increased risk of loss of independent living (adjusted risk ratio [RR] 1·18 [95% CI 1·13-1·23], p<0·0001) compared with no medication-induced deep sedation. There were 30 022 documented episodes of emotional distress. Having a high proportion of emotional distress was associated with a decreased risk of loss of independent living (RR 0·88 [0·84-0·92], p<0·0001) compared with no emotional distress. Clinicians provided deeper sedation in response to emotional distress and during the night (p<0·0001 for both comparisons). Symptom control with antipsychotics or non-opioid analgesics was associated with a decreased risk of loss of independent living compared with no treatment (RR 0·95 [0·91-0·99], p=0·013). Absence of patient mobility during mechanical ventilation was associated with loss of independent living (RR 1·32 [1·28-1·36], p<0·0001) and mediated 32·5% (p<0·0001) of the effects of deep sedation on loss of independent living.
> 
> INTERPRETATION: Among mechanically ventilated adults in an ICU, the proportion of time spent in medication-induced deep sedation was independently associated with loss of independent living. Lighter sedation, allowing for recognition of emotional distress and for patient mobility, was associated with a lower risk of loss of independent living.
> 
> FUNDING: Department of Anesthesiology, Montefiore Medical Center, Albert Einstein College of Medicine (New York, NY, USA).

> **中文摘要：**
> 背景：在无明确指征的情况下，深度镇静可用于有创机械通气，以缓解情绪困扰或失眠的体征与症状。然而，药物诱导的深度镇静与康复延迟和死亡率增加相关。我们检验了这样一个假设：药物诱导的深度镇静，而非情绪困扰，与失去独立生活能力相关。
> 
> 方法：在本回顾性队列研究中，我们纳入了在纽约布朗克斯区及邻近郡县的某学术医疗体系的 20 个重症监护病房（ICU）中接受机械通气时间 ≥24 小时、且入院前独立生活的成年患者（年龄≥18岁）。主要暴露变量是 ICU 入院首周内药物诱导深度镇静（定义为里士满躁动镇静评分 -3 至 -5）的时间比例。次要暴露变量是 ICU 入院首周内存在情绪困扰指征的时间比例。以上暴露被按比例分类为“无”、“低比例”或“高比例”，其中中位数（药物诱导深度镇静为 42.9%，情绪困扰为 10.7%）为高低分界。主要结局为失去独立生活能力（定义为院内死亡或术后出院至长期专业护理机构）。采用修正泊松回归并基于预设混杂因素控制模型评估暴露与结局之间的关联。还进行了中介分析，以评估机械通气期间的患者活动水平是否介导了深度镇静与失去独立生活能力之间的关系。
> 
> 结果：在 2016 年 1 月 30 日至 2023 年 7 月 11 日期间，共有 10,204 名接受有创机械通气的患者，其中 6,369 名（62.4%）失去了独立生活能力。接受深度镇静的患者比例平均比医嘱镇静的患者比例高 2.84 倍（标准差 1.51）。共有 7,289 名（71.4%）患者在机械通气首周至少出现一次药物诱导的深度镇静。与无药物诱导镇静相比，药物诱导深度镇静比例较高者失去独立生活能力的风险增加（调整后风险比 [RR] 1.18 [95% CI 1.13–1.23], p<0.0001）。共记录了 30,022 次情绪困扰事件。与无情绪困扰相比，情绪困扰比例较高者失去独立生活能力的风险较低（RR 0.88 [0.84–0.92], p<0.0001）。临床医生在应对情绪困扰或夜间时倾向于实施更深的镇静（两者 p<0.0001）。使用抗精神病药物或非阿片类镇痛药进行症状控制者较无治疗者失去独立生活能力的风险更低（RR 0.95 [0.91–0.99], p=0.013）。机械通气期间缺乏患者活动与失去独立生活能力显著相关（RR 1.32 [1.28–1.36], p<0.0001），并在深度镇静导致失去独立生活能力的效应中起到了 32.5%（p<0.0001）的中介作用。
> 
> 解释：在 ICU 接受机械通气的成年人中，药物诱导深度镇静的时间比例与失去独立生活能力独立相关。较浅的镇静——允许识别情绪困扰并促进患者活动——与较低的失能风险相关。
> 
> 资助：美国纽约蒙蒂菲奥里医学中心麻醉学系及爱因斯坦医学院。

### 第二部分 AI 大师评价

本研究基于纽约地区多中心 ICU 的回顾性队列，系统分析了药物诱导的深度镇静与机械通气患者功能恢复之间的关系。研究发现，高比例的深度镇静显著增加失去独立生活能力的风险，而保持轻度镇静、识别情绪困扰并促进早期活动可改善预后。该研究创新地将镇静深度、情绪反应及活动水平纳入统一模型，并通过中介分析阐明机制。尽管其观察性设计限制了因果推断，但为优化重症镇静管理提供了重要循证依据。

---

## 23. 异常的血小板与淋巴细胞比值与儿童脓毒症的不良结局相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40997309)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 40997309
**DOI：** 10.1097/SHK.0000000000002681

### 第一部分 原文与翻译

**英文原标题：** Abnormal Platelet-to-Lymphocyte Ratio is Associated with Poor Outcomes in Pediatric Sepsis.

> **英文摘要：**
> OBJECTIVE: Sepsis remains a major cause of morbidity and mortality in children, necessitating an early risk assessment to prevent delayed treatment and achieve optimal outcomes. This study investigated the association between systemic immune-inflammatory indices and clinical outcomes in children with sepsis.
> 
> DESIGN: Single-center, retrospective cohort study.
> 
> SETTING: Pediatric intensive care unit of a tertiary care children's hospital from 2015 to 2023.
> 
> PATIENTS: Children aged 0-18 years admitted with sepsis. Patients were excluded if they lacked a complete blood count with differential on admission.
> 
> RESULTS: In total, 420 patients were included. The platelet-to-lymphocyte ratio (PLR) was associated with higher mortality [hazard ratio 1.001 (1.000-1.002), P  = 0.032]. Incorporating PLR into the Pediatric Index of Mortality score improved the model discrimination for mortality (area under the receiver operator characteristic curves 0.705 vs. 0.774; area under the precision-recall curve 0.202 vs. 0.257). Similarly, adding PLR to the Pediatric Risk of Mortality-III improved the area under the receiver operator characteristic curves from 0.648 to 0.697. High PLR was also associated with higher odds of requiring intubation (OR 2.42, P  = 0.005) and extracorporeal membrane oxygenation (OR 4.74, P  = 0.002) and with decreased subdistribution hazard ratio of extubation, intensive care unit discharge, and hospital discharge alive at 28 days (subdistribution hazard ratio 0.89, 0.72, and 0.76, respectively; all P  < 0.005).
> 
> CONCLUSIONS: High PLR at admission was independently associated with worse clinical outcomes in pediatric patients with sepsis. Adding PLR to the Pediatric Index of Mortality and Pediatric Risk of Mortality-III enhanced the predictive performance. PLR is a simple and readily available index that may improve early risk stratification in this high-risk population.

> **中文摘要：**
> 目的：脓毒症仍是儿童发病率和死亡率的主要原因之一，因此需要早期风险评估，以防止治疗延误并获得最佳预后。本研究探讨全身免疫炎症指标与儿童脓毒症临床结局之间的关联。
> 
> 设计：单中心、回顾性队列研究。
> 
> 研究场所：2015年至2023年期间，一所三级儿童医院的儿科重症监护病房。
> 
> 研究对象：年龄为0–18岁的儿童脓毒症患者。入组标准要求入院时具备全血细胞计数及分类检测结果，否则予以排除。
> 
> 结果：共纳入420例患者。血小板与淋巴细胞比值（PLR）与较高的死亡风险相关［风险比1.001（1.000–1.002），P＝0.032］。将PLR纳入儿童死亡率指数（Pediatric Index of Mortality, PIM）评分后，死亡预测模型的区分能力得到改善（受试者工作特征曲线下面积由0.705升至0.774；精确率–召回曲线下面积由0.202升至0.257）。类似地，将PLR加入儿童死亡风险评分III（Pediatric Risk of Mortality-III, PRISM-III）后，曲线下面积从0.648提高至0.697。高PLR亦与更高的插管需求风险（比值比2.42，P＝0.005）及体外膜氧合需求（比值比4.74，P＝0.002）相关，同时与28天内拔管、重症监护病房出院及存活出院的亚分布风险比降低相关（分别为0.89、0.72和0.76；均P＜0.005）。
> 
> 结论：入院时高PLR与儿童脓毒症患者较差的临床结局独立相关。将PLR纳入儿童死亡率指数和儿童死亡风险评分III可提升预测性能。PLR是一种简单易得的指标，可用于提高此高危人群的早期风险分层能力。

### 第二部分 AI 大师评价

本研究通过大样本的回顾性队列分析，验证了血小板与淋巴细胞比值（PLR）在儿童脓毒症风险预测中的独立价值。结果显示，高PLR与更高的死亡率、插管及ECMO需求相关，并能增强现有风险评分模型的预测力。研究创新性在于将简单易测的炎症指标引入儿科脓毒症风险评估体系。其局限性包括单中心设计与回顾性性质，未来需多中心前瞻性验证。

---

## 24. 多中心智能研究中白细胞的血液生物标志物与拉曼分析：重症监护病房（Intelligence-1）和急诊科（Intelligence-2）研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40997262)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 40997262
**DOI：** 10.1097/SHK.0000000000002699

### 第一部分 原文与翻译

**英文原标题：** Blood Biomarker and Raman Analysis of Leukocytes in the Multicenter Intelligence Trials: At the Intensive Care Unit (Intelligence-1) and the Emergency Department (Intelligence-2).

> **英文摘要：**
> BACKGROUND: Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, goes along with a complex and not yet fully understood host response. Despite many different biomarkers, optimal screening tools to identify patients with sepsis are still needed. In a previous, single-center clinical trial with well-defined and well-separated patient cohorts, a new biophotonic marker based on the Raman spectroscopic characterization of leukocytes showed added value to stratify patients and identify infection and sepsis.
> 
> RESULTS: In the INTELLIGENCE studies, 279 patients from six centers in two countries were analyzed, and the Raman spectra of ~1500 leukocytes per patient were measured within only 1 hour. This marks a huge step from bench to bedside regarding usability and technology readiness level of Raman spectroscopy in multicentre clinical trials. With a discriminatory power comparable to individual conventional biomarkers (C-reactive protein, procalcitonin, interleukin-6, and soluble urokinase-type plasminogen activator receptor), the Raman score of leukocytes could not provide added value to the clinical discrimination of sepsis in the INTELLIGENCE-1 study cohorts of intensive care patients with infections. When translating the classification model from INTELLIGENCE-1 to the heterogeneous patient cohort recruited at the emergency department of the double-blinded INTELLIGENCE-2 trial, the Raman score failed to provide added value.
> 
> CONCLUSIONS: In theory, Raman assessment of leukocytes might still be a promising tool for sepsis diagnosis and patient stratification, but there is more basic, translational, and clinical research needed to refine its usability and clinical role, probably also taking questions of the pathophysiology of the dysregulated host response for a phenotype stratification into account.

> **中文摘要：**
> 背景：脓毒症被定义为由宿主对感染的不良调控反应引起的危及生命的器官功能障碍，其宿主反应复杂且尚未完全明了。尽管已经提出了许多不同的生物标志物，但仍然需要最佳的筛查工具来识别脓毒症患者。在先前一项具有明确且区分良好的患者队列的单中心临床试验中，一种基于白细胞拉曼光谱特征的新型生物光子标志物显示出在患者分层及感染与脓毒症识别方面的附加价值。
> 
> 结果：在 INTELLIGENCE 研究中，共分析了来自两个国家六个中心的279名患者，并在仅1小时内测得每位患者约1500个白细胞的拉曼光谱。这标志着拉曼光谱技术在多中心临床试验中从实验室到临床应用的可用性和技术成熟度方面迈出了重要一步。尽管白细胞拉曼评分的区分能力可与传统单个生物标志物（C反应蛋白、降钙素原、白介素-6和可溶性尿激酶型纤溶酶原激活物受体）相当，但在 INTELLIGENCE-1 研究的感染性重症监护患者队列中，拉曼评分未能在脓毒症的临床鉴别中提供额外价值。当将来自 INTELLIGENCE-1 的分类模型应用于双盲 INTELLIGENCE-2 试验中急诊科收治的异质性患者队列时，拉曼评分同样未能提供额外价值。
> 
> 结论：理论上，白细胞的拉曼评估仍可能是脓毒症诊断和患者分层的有前景工具，但其可用性和临床角色仍需更多基础、转化及临床研究加以完善，或许还需结合宿主反应失调的病理生理机制来进行表型分层的考量。

### 第二部分 AI 大师评价

本研究旨在评估利用白细胞拉曼光谱特征作为脓毒症筛查生物标志物的可行性与临床价值。研究整合了多中心、大样本数据，验证了该技术从实验室到临床应用的可操作性。结果表明，白细胞拉曼评分虽具与传统炎症标志物相当的区分能力，但未能显著提升脓毒症的临床诊断价值。该研究创新性地探索了光谱学在脓毒症精准分层中的潜力，但其局限在于模型的泛化能力不足及临床效益尚未充分体现。

---

## 25. 加蓬儿童中放射减毒全孢子疟疾疫苗的安全性、耐受性及保护效力：一项随机、双盲、安慰剂对照的Ⅱ期试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40972633)
**期刊：** The Lancet. Infectious diseases
**PMID：** 40972633
**DOI：** 10.1016/S1473-3099(25)00434-7

### 第一部分 原文与翻译

**英文原标题：** Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial.

> **英文摘要：**
> BACKGROUND: Highly effective malaria vaccines are crucial to further reduce the burden of malaria. The radiation-attenuated Plasmodium falciparum sporozoite (PfSPZ) Vaccine protects adults; however, there are insufficient efficacy data in child populations. We aimed to assess the safety and efficacy of the PfSPZ Vaccine in children aged 1-12 years in Gabon.
> 
> METHODS: This randomised, double-blind, placebo-controlled, phase 2 trial was conducted at the Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon. Healthy children were stratified by age (1-2, 3-6, and 7-12 years) and allocated 2:1 by block randomisation to receive 9·0 × 10 PfSPZ Vaccine or placebo (normal saline), administered by direct venous inoculation on days 1, 8, and 29. Artemether-lumefantrine was given before the third vaccination to clear latent parasitaemia. The co-primary endpoints were safety, evaluated in the intention-to-treat population by severe adverse events within 7 days (solicited) and 28 days (unsolicited) of vaccination and by serious adverse events; and vaccine efficacy, measured as time to first P falciparum-positive thick blood smear (TBS), 2-26 weeks after immunisation in those who received three vaccinations (ie, the modified intention-to-treat population). The trial was registered at ClinicalTrials.gov, NCT03521973, and is complete.
> 
> FINDINGS: Between June 21, 2018, and April 30, 2019, 345 children were assessed for eligibility, of whom 200 were enrolled to the study: 134 were allocated to receive PfSPZ Vaccine and 66 to receive placebo. 192 participants received three vaccinations and comprised the modified intention-to-treat population. Systemic adverse events were reported by 33 (25%) of 134 participants in the vaccine group (47 events) and 15 (23%) of 66 participants in the placebo group (25 events); subjective fever was the most reported event in both groups. Three grade 3 systemic adverse events were reported (two cases of elevated body temperature and one case of subjective fever), all in the placebo group. 32 serious adverse events were reported across 22 study participants, 13 (10%) of 134 in the vaccine group and nine (14%) of 66 in the placebo group, all of which were considered unrelated to the intervention. There were no treatment-related deaths. 25 (19%) of 129 vaccine recipients and 14 (23%) of 63 placebo recipients became TBS-positive for P falciparum at 2-26 weeks after vaccination. The age-stratum-adjusted vaccine efficacy (1 - hazard ratio) was 9% (95% CI -75 to 53; p=0·78).
> 
> INTERPRETATION: PfSPZ Vaccine is well tolerated and safe, but it did not prevent P falciparum infection in children in Gabon. Whether presumptive treatment during immunisation or more potent PfSPZ vaccines can establish vaccine efficacy is currently under investigation.
> 
> FUNDING: German Center for Infection Research, European and Developing Countries Clinical Trials Partnership, National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Sanaria.

> **中文摘要：**
> 背景：高效的疟疾疫苗对于进一步减轻疟疾负担至关重要。放射减毒恶性疟原虫孢子疫苗（PfSPZ Vaccine）可对成年人提供保护；然而，目前关于儿童人群的有效性数据不足。本研究旨在评估该疫苗在加蓬1–12岁儿童中的安全性和有效性。
> 
> 方法：这项随机、双盲、安慰剂对照的Ⅱ期临床试验在加蓬兰巴雷内医学研究中心进行。健康儿童按年龄（1–2岁、3–6岁、7–12岁）分层，并以区组随机法按2:1比例分配至接种9.0×10个PfSPZ疫苗或安慰剂（生理盐水），通过静脉直接注射于第1、8及29天进行接种。在第三次接种前给予蒿甲醚-卢米芬特林以清除潜在血寄生虫感染。主要共同终点包括：安全性（在全分析集人群中，评估接种后7天内的预期严重不良事件、28天内的非预期不良事件以及严重不良事件）及疫苗有效性（在接受三次接种的修正全分析集人群中，以接种后第2至26周首次厚血涂片检出恶性疟原虫阳性的时间为指标）。本试验注册号为ClinicalTrials.gov NCT03521973，现已完成。
> 
> 结果：2018年6月21日至2019年4月30日期间，共筛选345名儿童，其中200名入组：134名分配至PfSPZ疫苗组，66名分配至安慰剂组。共有192名参与者完成三次接种，构成修正全分析集人群。疫苗组134名参与者中33人（25%，47起事件）及安慰剂组66名参与者中15人（23%，25起事件）报告全身性不良事件，主观发热为两组中最常见事件。共报告3例3级全身性不良事件（2例体温升高、1例主观发热），均发生于安慰剂组。共有32起严重不良事件，涉及22名参与者，其中疫苗组13人（10%）和安慰剂组9人（14%）；所有事件均被认为与试验干预无关。未出现与治疗相关的死亡。接种后第2至26周内，疫苗组129人中25人（19%）和安慰剂组63人中14人（23%）出现恶性疟原虫厚血涂片阳性。按年龄分层调整后的疫苗有效性（1－风险比）为9%（95%置信区间：－75至53；p=0.78）。
> 
> 解释：PfSPZ疫苗耐受性良好且安全，但未能在加蓬儿童中预防恶性疟原虫感染。是否通过免疫时的预防性治疗或更高效的PfSPZ疫苗能够建立显著的保护效果，仍需进一步研究。
> 
> 资金来源：德国感染研究中心、欧盟与发展中国家临床试验伙伴计划、美国国家过敏与传染病研究所、美国国立卫生研究院及Sanaria公司。

### 第二部分 AI 大师评价

本研究通过在加蓬儿童中开展随机、双盲、安慰剂对照的Ⅱ期临床试验，系统评估了放射减毒全孢子PfSPZ疟疾疫苗的安全性与保护效力。结果显示，疫苗安全且耐受性良好，但未能显著降低恶性疟原虫感染风险。该研究在儿童群体中提供了重要的现场数据，填补了PfSPZ疫苗年龄层效能研究的空白。虽未观察到保护效应，但研究提示免疫策略或疫苗制剂仍有改进潜力，为后续优化疟疾疫苗研发提供了科学依据。

---

## 26. 含氯法齐明和利福喷汀的 3 个月治疗方案治疗药物敏感型结核病与标准方案比较（Clo-Fast）：一项随机、开放标签的 2c 期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40915311)
**期刊：** The Lancet. Infectious diseases
**PMID：** 40915311
**DOI：** 10.1016/S1473-3099(25)00436-0

### 第一部分 原文与翻译

**英文原标题：** A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.

> **英文摘要：**
> BACKGROUND: Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose, to the standard 6 month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol in drug-susceptible tuberculosis.
> 
> METHODS: Clo-Fast was a phase 2c open-label trial recruiting participants at six sites in five countries. Participants aged 18 years or older with pulmonary tuberculosis who were sputum smear positive for acid-fast bacilli or molecular tuberculosis assay positive (with Mycobacterium tuberculosis with sensitivity to rifampicin and isoniazid) were eligible for enrolment. Individuals with HIV infection with a CD4 cell count ≥100 cells per mm could participate. Participants were randomly assigned in a 2:1 ratio (group 1: group 2) or a 2:1:1 ratio (group 1: group 2: group 3), depending on consent to participate in the intensive pharmacokinetic visits required in group 3, using a central web-based system with permuted blocks. The group 1 regimen included 8 weeks of rifapentine-isoniazid-pyrazinamide-ethambutol-clofazimine, with a 2-week 300 mg clofazimine loading dose, followed by 5 weeks of rifapentine-isoniazid-pyrazinamide-clofazimine (13 weeks total). The group 2 control regimen included 8 weeks of isoniazid-rifampicin-pyrazinamide-ethambutol followed by 18 weeks of rifampicin-isoniazid. Group 3 was identical to group 1 over the first 4 weeks of treatment, except that the regimen was administered without a clofazimine loading dose (100 mg daily); after 4 weeks of group 3 treatment, participants transitioned to local standard of care to complete treatment. Group 3 was designed to assess the effect of a 2-week loading dose on clofazimine pharmacokinetics. Randomisation was stratified by HIV status and advanced disease on chest radiograph. The primary efficacy endpoint was time to sputum culture-negative status by 12 weeks. The primary safety endpoint was the proportion of participants experiencing any grade 3 or worse adverse event over 65 weeks. The key secondary endpoint was unfavourable clinical or bacteriological outcomes by week 65. The efficacy analysis population contained participants assigned to groups 1 and 2 who were not late exclusions (no positive culture at screening, entry, or week 1, or if rifampicin resistance or isoniazid resistance was detected at screening or entry); the safety analysis population contained all randomly assigned participants who took at least one dose of treatment. The trial was registered with ClinicalTrials.gov ID: NCT04311502.
> 
> FINDINGS: 104 participants were randomly assigned to group 1 (n=58), group 2 (n=31), and group 3 (n=15). 82 (79%) were male and 74 (71%) had radiographically advanced disease; 30 (29%) were people with HIV. The trial was stopped early for lack of clinical efficacy. For the primary efficacy outcome, 49 (89%) of 55 group 1 participants and 28 (90%) of 31 group 2 participants had stable sputum culture conversion by week 12 (adjusted hazard ratio 1·21 [90% CI 0·82-1·79]; p=0·2089). Adverse events grade 3 or worse occurred in 26 (45%) of 58 group 1 participants and five (16%) of 31 group 2 participants (difference 30%, 90% CI 14-45; p=0·002). The cumulative probability of a week 65 unfavourable outcome was 52% (95% CI 37-69) in group 1 versus 27% (14-50) in group 2 (p=0·049).
> 
> INTERPRETATION: Although the trial was stopped early, we found that a 3-month regimen containing clofazimine and rifapentine had 12-week culture conversion rates that did not differ statistically from the standard of care. The regimen was associated with an unacceptably high proportion of participants with unfavourable composite clinical outcomes and grade 3 or worse adverse events.
> 
> FUNDING: US National Institutes of Health Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) and the National Institute of Allergy and Infectious Diseases.

> **中文摘要：**
> 背景：基于临床前和临床研究结果，由异烟肼、利福喷汀、吡嗪酰胺、乙胺丁醇和氯法齐明组成的五药联合方案被认为具备缩短药物敏感型结核病治疗周期的潜力；Clo-Fast 试验旨在评估此方案的疗效和安全性。我们将为期 3 个月的异烟肼、利福喷汀、吡嗪酰胺、乙胺丁醇和氯法齐明方案（配合氯法齐明负荷剂量给药），与标准的 6 个月异烟肼、利福平、吡嗪酰胺和乙胺丁醇方案进行比较。
> 
> 方法：Clo-Fast 为一项 2c 期开放标签试验，在五个国家的六个中心招募参与者。年龄 ≥18 岁且痰涂片抗酸杆菌阳性或分子检测结核病阳性（且结核分枝杆菌对利福平和异烟肼敏感）的肺结核患者可入选。CD4 细胞计数 ≥100 个/mm³ 的 HIV 感染者可参加。参与者通过中央网络系统采用区组随机法，按 2:1（组 1: 组 2）或 2:1:1（组 1: 组 2: 组 3）比例随机分组，取决于是否同意参加组 3 所需的药代动力学密集访视。组 1 方案包括 8 周利福喷汀–异烟肼–吡嗪酰胺–乙胺丁醇–氯法齐明治疗，并给予为期 2 周、300 mg 的氯法齐明负荷剂量，之后再进行 5 周的利福喷汀–异烟肼–吡嗪酰胺–氯法齐明治疗（共 13 周）。组 2 标准对照方案包括 8 周异烟肼–利福平–吡嗪酰胺–乙胺丁醇治疗，随后 18 周利福平–异烟肼治疗。组 3 在治疗前 4 周与组 1 相同，但不给予氯法齐明负荷剂量（每日 100 mg）；4 周后，组 3 患者转入当地标准治疗以完成疗程。组 3 的设计旨在评估 2 周负荷剂量对氯法齐明药代动力学的影响。随机分层因素包括 HIV 状态和胸片上是否存在进展性病变。主要疗效终点为 12 周内痰培养转阴所需时间；主要安全性终点为 65 周内发生 3 级或更严重不良事件者比例。关键次要终点为 65 周内不良临床或细菌学结果的比例。疗效分析人群包括分配入组 1 和组 2 且未被后期排除的参与者（筛查、入组或第 1 周痰培养阳性，或检测出利福平或异烟肼耐药者均被排除）。安全性分析人群包括所有随机分配且至少接受一剂治疗的参与者。试验在 ClinicalTrials.gov 注册（编号 NCT04311502）。
> 
> 结果：共 104 名参与者被随机分入组 1（n=58）、组 2（n=31）和组 3（n=15）。其中 82 人（79%）为男性，74 人（71%）影像学显示为进展性病变；30 人（29%）为 HIV 感染者。因缺乏临床疗效，试验提前终止。在主要疗效指标上，55 名组 1 参与者中有 49 名（89%），31 名组 2 参与者中有 28 名（90%）于第 12 周时痰培养稳定转阴（校正后风险比 1.21 [90% CI 0.82–1.79]; p=0.2089）。3 级或更严重不良事件在组 1 有 26 例（45%）发生，在组 2 有 5 例（16%）（差异 30%，90% CI 14–45；p=0.002）。至第 65 周，不良结局累积概率为组 1 的 52%（95% CI 37–69），组 2 的 27%（14–50）（p=0.049）。
> 
> 结论：尽管试验提前终止，我们发现含氯法齐明和利福喷汀的 3 个月方案在 12 周内的痰培养转阴率与标准治疗相比无统计学差异，但其与较高比例的不良综合临床结局及 3 级或更严重不良事件相关。
> 
> 资金来源：美国国立卫生研究院（NIH）HIV/艾滋病及其他感染全球临床治疗推进计划（ACTG）与美国国家过敏与传染病研究所（NIAID）。

### 第二部分 AI 大师评价

本研究旨在评估一种包含氯法齐明与利福喷汀的三个月新型短程治疗方案用于药物敏感型结核病的疗效与安全性。试验采用多国、多中心的开放标签随机设计，与当前六个月标准疗法进行比较。结果显示，尽管新方案在十二周时的痰培养转阴率与标准治疗相当，但其不良事件（≥3级）与不良结局比例显著较高，导致研究提前终止。研究的创新在于探索潜在治疗周期缩短的可行性，但安全性不足成为主要限制。

---

## 27. 接受住院治疗的COVID-19患者中索特罗韦单抗与常规治疗的比较（RECOVERY试验）：一项随机、对照、开放标签、平台式试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40886716)
**期刊：** The Lancet. Infectious diseases
**PMID：** 40886716
**DOI：** 10.1016/S1473-3099(25)00361-5

### 第一部分 原文与翻译

**英文原标题：** Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

> **英文摘要：**
> BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital with COVID-19.
> 
> METHODS: Patients admitted with COVID-19 pneumonia to 107 UK hospitals were randomly assigned (1:1) to either usual care alone or usual care plus a single 1 g infusion of sotrovimab, using web-based unstratified randomisation. Participants were eligible if they were aged at least 18 years, or aged 12-17 years if weighing at least 40kg, and had confirmed COVID-19 pneumonia with no medical history that would put them at significant risk if they participated in the trial. Participants were retrospectively categorised as having a high antigen level if baseline serum SARS-CoV-2 nucleocapsid antigen was above the median concentration (the prespecified primary efficacy population), otherwise they were categorised as having a low antigen level. The primary outcome was 28-day mortality assessed by intention to treat. Safety outcomes were assessed among all participants, regardless of antigen level. Recruitment closed on March 31, 2024, when funding ended. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
> 
> FINDINGS: From Jan 4, 2022, to March 19, 2024, 1723 patients were enrolled in the RECOVERY sotrovimab comparison. Of these, 828 (48%) were assigned to usual care plus sotrovimab and 895 (52%) were assigned to usual care only. Mean patient age was 70·7 years (SD 14·8) and 1033 (60%) were male. 720 (42%) patients were classified as having a high antigen level, 717 (42%) as having a low antigen level, and 286 (17%) had unknown antigen status. 1389 (81%) patients were vaccinated, 1179 (82%) of 1438 patients with known serostatus had anti-spike antibodies at randomisation, and 1021 (>99%) of 1026 patients with sequenced samples were infected with omicron variants. Among patients with a high antigen level, 82 (23%) of 355 assigned to sotrovimab versus 106 (29%) of 365 assigned usual care died within 28 days (rate ratio 0·75, 95% CI 0·56-0·99; p=0·046). In an analysis of all randomly assigned patients (regardless of antigen status), 177 (21%) of 828 patients assigned to sotrovimab versus 201 (22%) of 895 assigned to usual care died within 28 days (0·95, 0·77-1·16; p=0·60). Infusion reactions were recorded in 12 (2%) of 781 patients receiving sotrovimab. We found no difference between groups in any other safety outcome.
> 
> INTERPRETATION: In patients admitted to hospital with COVID-19 pneumonia, sotrovimab was associated with reduced mortality in the primary analysis population who had a high serum SARS-CoV-2 antigen concentration at baseline, but not in the overall population. Treatment options for patients admitted to hospital are limited, and mortality in those receiving current standard of care was high. The emergence of high-level resistance to sotrovimab among subsequent SARS-CoV-2 variants restricts its current usefulness, but these results indicate that targeted neutralising antibody therapy could potentially still benefit some patients admitted to hospital who are at high risk of death in an era of widespread vaccination and omicron infection.
> 
> FUNDING: UK Research and Innovation (Medical Research Council) and National Institute for Health and Care Research.

> **中文摘要：**
> 背景：索特罗韦单抗是一种针对SARS-CoV-2刺突蛋白的中和单克隆抗体。我们旨在在RECOVERY试验中评估索特罗韦单抗的疗效和安全性。该试验由研究者发起，为一项个体随机、对照、开放标签、可适应的平台试验，用于评估住院COVID-19患者的治疗方法。
> 
> 方法：在英国107家医院的COVID-19肺炎住院患者中，按1:1比例随机分配至仅接受常规治疗或接受常规治疗加一次性1克索特罗韦单抗静脉输注。随机化通过基于网络的非分层方式进行。纳入标准包括：年龄至少18岁，或12-17岁且体重不低于40公斤；确诊COVID-19肺炎，且无参与试验会造成重大风险的医学病史。根据基线血清SARS-CoV-2核壳抗原水平（高于中位数者为预设的主要疗效人群），参与者被回顾性分为高抗原水平组或低抗原水平组。主要结局为28天全因死亡率（基于意向治疗分析）。安全性终点在所有参与者中评估，不论抗原水平。招募于2024年3月31日因经费终止而结束。试验注册号为ISRCTN（50189673）和ClinicalTrials.gov（NCT04381936）。
> 
> 结果：自2022年1月4日至2024年3月19日，共纳入1723例患者。其中，828例（48%）分配至索特罗韦单抗组，895例（52%）分配至常规治疗组。平均年龄70.7岁（标准差14.8），男性1033例（60%）。720例（42%）属于高抗原组，717例（42%）为低抗原组，286例（17%）抗原状态未知。共有1389例（81%）患者接种过疫苗，在1438例有血清学结果的患者中，1179例（82%）随机时检测到抗刺突抗体；在1026例有病毒测序结果的患者中，1021例（>99%）感染奥密克戎变异株。在高抗原组中，索特罗韦单抗组355例中有82例（23%）在28天内死亡，而常规治疗组365例中有106例（29%）死亡（比率比0.75，95%置信区间0.56–0.99，p=0.046）。在所有随机患者的总体分析中（不论抗原水平），索特罗韦单抗组828例中死亡177例（21%），常规治疗组895例中死亡201例（22%）（比率比0.95，95%置信区间0.77–1.16，p=0.60）。在索特罗韦单抗组781例中有12例（2%）出现输注反应。两组在其他安全性结局上无显著差异。
> 
> 解释：在因COVID-19肺炎住院的患者中，索特罗韦单抗在基线血清SARS-CoV-2抗原浓度较高的主要分析人群中与降低的死亡率相关，但在总体人群中未观察到相同结果。针对住院患者的治疗选择仍然有限，当前标准治疗下的死亡率仍较高。随着后续变异株对索特罗韦单抗产生高度耐药性，其现阶段的应用受限，但本研究结果提示，在广泛疫苗接种和奥密克戎流行的时代，靶向中和抗体治疗仍可能惠及部分高危住院患者。
> 
> 资助来源：英国研究与创新（医学研究委员会）与国家健康与护理研究院。

### 第二部分 AI 大师评价

本研究通过RECOVERY平台试验系统评估了索特罗韦单抗在住院COVID-19患者中的疗效与安全性。试验设计严谨，样本量充足，发现其仅在基线病毒抗原水平较高的患者中可降低28天死亡率，而对总体人群无显著益处。研究突出了个体化抗体治疗的潜在价值，也揭示了因病毒变异导致疗效受限的现实问题。尽管药物当前临床应用受阻，但结果为未来针对特定人群的中和抗体精确治疗提供了重要参考。

---

## 28. 重症患者组织灌注与液体反应性的评估：采用Ikorus尿道光电体积描记设备的可行性初步研究（TARGET-UP研究）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40729501)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 40729501
**DOI：** 10.1097/SHK.0000000000002672

### 第一部分 原文与翻译

**英文原标题：** Tissue Perfusion and Fluid Responsiveness Assessment in Critically Ill Patients. A Feasibility Pilot Study Using the Ikorus Urothelial Plethysmography Device (The Target-Up Study).

> **英文摘要：**
> BACKGROUND: Accurate assessment of tissue perfusion is challenging. Commonly used markers like lactate levels and central venous oxygen saturation are indirect, intermittent, and provide a global picture of circulatory status which may not reflect perfusion at the organ level. The Urethral Perfusion Index (UPi), measured through a specialized urinary catheter, is a novel technique that offers continuous, real-time monitoring of perfusion in a central tissue bed, potentially providing more immediate and targeted clinical information.
> 
> OBJECTIVES: 1. The aims of the study were (1) to assess the correlation between changes to left ventricular outflow tract velocity time integral (LVOT VTi) and UPi following a fluid challenge and (2) To assess the relationship between UPi and other markers of tissue perfusion.
> 
> DESIGN: Interventional, feasibility pilot study.
> 
> SETTING: Single-center, study conducted at a tertiary-level institution in the United Kingdom. All patients were mechanically ventilated adults, whom the primary clinical team thought would benefit from a fluid challenge.
> 
> INTERVENTION: A fluid challenge (FC) was defined as a 250 mL bolus of crystalloid solution.
> 
> MAIN OUTCOME MEASURES: Focused transthoracic echocardiogram measured LVOT VTi and UPi, measured before and after FC.
> 
> RESULTS: There were no reported complications associated with device use or insertion. Mean duration of data recorded was 19 h and the Signal Quality Index of the UPi trace was high (93%). There was a moderate positive correlation between the time matched values of UPi and LVOT VTi (Spearman r = 0.55, P  < 0.0001), R 2 value of 0.272. However, there was no discernible correlation seen between change in UPi and VTi following fluid (Spearman r = 0.24, P  = 0.14). Patients with below-average UPi at baseline had evidence of poorer systemic tissue perfusion, as measured by lactate concentration and capillary refill time, and received more vasoactive drugs.
> 
> CONCLUSION: UPi may be a marker of tissue perfusion in a diverse group of critically ill patients. With further evaluation it may, therefore, present a future therapeutic target. Although there is some relationship between LVOT VTi and UPi, it is not precise enough to be used as a marker of fluid responsiveness.
> 
> TRIAL REGISTRATION: London Southeast Research and Ethics Committee (22/LO/0911).

> **中文摘要：**
> 背景：准确评估组织灌注具有挑战性。目前常用的标志物如乳酸水平和中心静脉血氧饱和度均属于间接和间歇性指标，只能提供全身循环状况的总体概况，可能无法反映器官层面的灌注。通过专用导尿管测量的尿道灌注指数（UPi）是一种新技术，能够对中心组织床的灌注进行连续、实时监测，可能为临床提供更及时和更具针对性的信息。
> 
> 目标：本研究旨在：（1）评估液体负荷后左心室流出道速度时间积分（LVOT VTi）变化与UPi变化之间的相关性；（2）评估UPi与其他组织灌注指标之间的关系。
> 
> 研究设计：干预性、可行性初步研究。
> 
> 研究环境：单中心研究，地点位于英国一家三级医疗机构。所有受试者均为接受机械通气的成年患者，且其主要临床团队认为其可能从液体挑战中获益。
> 
> 干预措施：液体挑战（FC）定义为快速输入250毫升晶体液。
> 
> 主要结局指标：通过聚焦经胸超声心动图测量LVOT VTi，并在液体挑战前后测量UPi。
> 
> 结果：未报告与设备使用或置入相关的并发症。平均记录时长为19小时，UPi信号质量指数高（93%）。UPi与同时段LVOT VTi之间存在中度正相关（Spearman r = 0.55，P < 0.0001），决定系数R²为0.272。然而，液体输入后UPi与VTi变化之间未观察到显著相关性（Spearman r = 0.24，P = 0.14）。基线UPi低于平均值的患者，其全身组织灌注较差（乳酸浓度和毛细血管再充盈时间较差），且使用了更多血管活性药物。
> 
> 结论：UPi可能是重症患者组织灌注的一个潜在指标。经过进一步评估后，该指标或可作为未来的治疗靶点。尽管LVOT VTi与UPi之间存在一定关系，但其相关性不足以用于判断液体反应性。
> 
> 试验注册：伦敦东南研究伦理委员会（22/LO/0911）。

### 第二部分 AI 大师评价

本研究探索了一种基于尿道灌注指数（UPi）的新技术，用于实时评估重症患者的组织灌注状态。研究通过液体挑战结合超声测量LVOT VTi，评估UPi的可行性和相关性。结果显示UPi与LVOT VTi存在中度相关，但不足以预测液体反应性；低UPi患者表现出更差的灌注状态。研究创新地提出了中心组织即时灌注监测的概念，但样本量有限且为初步研究，需进一步验证临床应用价值。

---

## 29. 肠-肝轴代谢物与脓毒症：来自孟德尔随机化研究的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40720360)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 40720360
**DOI：** 10.1097/SHK.0000000000002667

### 第一部分 原文与翻译

**英文原标题：** Gut-Liver Axis Metabolites and Sepsis: Insights from Mendelian Randomization.

> **英文摘要：**
> BACKGROUND: Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection. Alterations in gut-liver axis metabolites, particularly bile acids, are commonly observed in sepsis. However, the associations between bile acids and sepsis risk or outcomes remain unclear. This study aimed to investigate the potential associations between genetically predicted levels of gut-liver axis metabolites-primarily bile acids-and sepsis risk and prognosis using bidirectional two-sample Mendelian randomization (MR), multivariable MR, and two-step mediation MR analyses.
> 
> METHODS: Genetic instruments for circulating bile acids were obtained from genome-wide association studies (GWAS) curated in the OpenGWAS database. Summary-level data for sepsis and 28-day mortality were derived from the UK Biobank. We conducted bidirectional two-sample MR to assess the associations between nine bile acids and both sepsis incidence and short-term prognosis. In addition, two-step mediation MR was performed to evaluate whether the associations between specific bile acids and sepsis risk might be mediated through intermediate traits, such as liver function markers. The statistical significance of mediation effects was further tested using both the Sobel test and bootstrap resampling methods.
> 
> RESULTS: Univariable MR analyses suggested that higher genetically predicted levels of taurodeoxycholate acid (TDCA) were associated with a lower risk of sepsis (OR = 0.797, 95% CI: 0.668-0.952, P  = 0.012). In contrast, glycocholate acid (GCA) (OR = 1.964, 95% CI: 1.220-3.164, P  = 0.005) and taurochenodeoxycholate acid (TCDCA) (OR = 1.998, 95% CI: 1.085-3.678, P  = 0.026) were positively associated with an increased 28-day mortality risk among sepsis patients. Results from the two-step mediation MR analysis indicated that alanine aminotransferase (ALT) may act as a mediator in the association between ursodeoxycholate acid (UDCA) and sepsis risk. The statistical significance of this mediation effect was further supported by both the Sobel test and bootstrap resampling analysis, suggesting that UDCA may be associated with a reduced risk of sepsis, at least in part, through its influence on circulating ALT levels.
> 
> CONCLUSIONS: This MR study provides genetic evidence consistent with potential relationships between specific bile acids and sepsis risk and prognosis. Taurodeoxycholate acid (TDCA) may be associated with a reduced risk of sepsis, whereas glycocholate acid (GCA) and taurochenodeoxycholate acid (TCDCA) might relate to worse outcomes. Moreover, among these liver enzymes, ALT exhibited the most significant mediation effect, suggesting that it may play a crucial role in the process by which UDCA influences the occurrence of sepsis. These findings suggest a possible role of bile acids in the pathophysiology of sepsis and may inform future mechanistic studies or therapeutic considerations.

> **中文摘要：**
> 背景：脓毒症是一种危及生命的综合征，其特征是宿主对感染的反应失调。肠-肝轴代谢物，特别是胆汁酸的改变，在脓毒症中常被观察到。然而，胆汁酸与脓毒症风险或预后的关系仍不清楚。本研究旨在利用双向双样本孟德尔随机化（MR）、多变量MR及两步中介MR分析，探讨遗传学预测的肠-肝轴代谢物（主要为胆汁酸）水平与脓毒症风险及预后的潜在关联。
> 
> 方法：循环胆汁酸的遗传工具变量来自OpenGWAS数据库中整理的全基因组关联研究（GWAS）。脓毒症及28天病死率的汇总数据来源于英国生物样本库（UK Biobank）。我们进行了双向双样本MR分析，以评估九种胆汁酸与脓毒症发生率以及短期预后的关联。此外，实施两步中介MR分析，以评估特定胆汁酸与脓毒症风险之间的关系是否通过中介特征（如肝功能标志物）实现。中介效应的统计显著性进一步通过Sobel检验和自助重采样法进行验证。
> 
> 结果：单变量MR分析表明，遗传学预测的牛磺去氧胆酸（TDCA）水平升高与较低的脓毒症风险相关（OR＝0.797，95%CI：0.668–0.952，P＝0.012）。相反，甘氨胆酸（GCA）（OR＝1.964，95%CI：1.220–3.164，P＝0.005）和牛磺鹅去氧胆酸（TCDCA）（OR＝1.998，95%CI：1.085–3.678，P＝0.026）与脓毒症患者28天死亡风险升高呈正相关。两步中介MR分析结果显示，丙氨酸氨基转移酶（ALT）可能在熊去氧胆酸（UDCA）与脓毒症风险之间起中介作用。Sobel检验和自助重采样法进一步支持了该中介效应的统计显著性，提示UDCA可能至少部分通过影响循环ALT水平而与降低脓毒症风险相关。
> 
> 结论：本MR研究提供了支持特定胆汁酸与脓毒症风险及预后之间潜在关系的遗传学证据。牛磺去氧胆酸（TDCA）可能与降低脓毒症风险相关，而甘氨胆酸（GCA）和牛磺鹅去氧胆酸（TCDCA）则可能与较差预后相关。此外，在肝酶中，ALT表现出最显著的中介效应，提示其在UDCA影响脓毒症发生的过程中可能发挥关键作用。这些发现提示胆汁酸可能在脓毒症的病理生理过程中具有潜在作用，为未来机制研究或治疗策略提供参考。

### 第二部分 AI 大师评价

该研究通过孟德尔随机化方法探讨了胆汁酸与脓毒症风险及预后之间的遗传关联，具有较强的因果推断价值。研究发现不同胆汁酸在脓毒症中呈现相反效应，其中TDCA可能具有保护作用，而GCA与TCDCA则与预后不良相关。研究的创新之处在于使用双向及两步中介MR分析，揭示了ALT在UDCA与脓毒症风险关联中的潜在中介作用。然而，结果仍需在不同种群和前瞻性研究中验证，以厘清其生物学机制。

---

## 30. 袖囊漏气试验结果与再次插管风险的关联：一项回顾性分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40705394)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 40705394
**DOI：** 10.1097/SHK.0000000000002674

### 第一部分 原文与翻译

**英文原标题：** Association Between Cuff Leak Test Results and Reintubation Risk: A Retrospective Analysis.

> **英文摘要：**
> BACKGROUND: Postextubation airway obstruction represents a significant complication in critical care, potentially necessitating reintubation and prolonging intensive care unit (ICU) stay. The cuff leak test (CLT) is commonly used to predict postextubation stridor and reintubation risk, but its clinical utility remains controversial. This study evaluated the relationship between CLT results and reintubation risk in a large cohort of critically ill patients.
> 
> METHODS: This single-center, retrospective, descriptive study analyzed 742 adult patients admitted to the medical and surgical ICUs who underwent mechanical ventilation for ≥24 h between January 2020 and December 2024. The primary outcome was reintubation within 48 h of planned extubation. Quantitative cuff leak volume measurements were performed preextubation, with leak volume expressed as absolute values and percentage of tidal volume. Multivariable logistic regression was used to identify independent predictors of reintubation, including CLT results and patient characteristics.
> 
> RESULTS: Of the 742 patients studied, 68 (9.2%) required reintubation within 48 h. Patients with a cuff leak volume <110 mL or <15% of tidal volume had significantly higher reintubation rates (18.7% vs. 7.1%, P  < 0.001). After adjusting for confounding variables, a positive CLT (defined as cuff leak volume <110 mL) remained independently associated with reintubation (adjusted odds ratio, 2.86; 95% confidence interval [CI], 1.65-4.97; P  < 0.001). Other significant independent predictors included prolonged intubation (>7 days), female sex, body mass index >30 kg/m 2 , and traumatic or difficult intubation. Combining CLT results with these clinical risk factors improved prediction accuracy (area under the curve, 0.82; 95% CI, 0.76-0.87).
> 
> CONCLUSION: A positive CLT is independently associated with increased reintubation risk in critically ill patients. The predictive accuracy is enhanced when CLT results are combined with clinical risk factors. These findings suggest that CLT should be incorporated into extubation decision-making, particularly for patients with additional risk factors for postextubation airway complications.

> **中文摘要：**
> 背景：拔管后气道梗阻是重症监护中的一项重要并发症，可能需要再次插管并延长重症监护病房（ICU）住院时间。袖囊漏气试验（CLT）常被用于预测拔管后喘鸣及再次插管风险，但其临床实用性仍存在争议。本研究评估了在大量重症患者中，CLT结果与再次插管风险之间的关系。
> 
> 方法：本单中心回顾性描述性研究分析了2020年1月至2024年12月期间，在内科和外科ICU中接受机械通气≥24小时的742例成年患者。主要结局为计划拔管后48小时内再次插管。拔管前进行了袖囊漏气量的定量测定，漏气量以绝对值和潮气量百分比表示。采用多变量逻辑回归分析确定再次插管的独立预测因素，包括CLT结果及患者特征。
> 
> 结果：在742例患者中，有68例（9.2%）于拔管后48小时内需要再次插管。袖囊漏气量＜110 mL或＜潮气量15%的患者，其再次插管率显著更高（18.7% vs. 7.1%，P < 0.001）。在校正混杂变量后，阳性CLT（定义为袖囊漏气量＜110 mL）仍与再次插管呈独立关联（调整后比值比2.86；95%置信区间[CI]，1.65-4.97；P < 0.001）。其他显著的独立预测因素包括插管时间延长（＞7天）、女性、体重指数＞30 kg/m²，以及创伤性或困难插管。将CLT结果与这些临床风险因素结合可提高预测准确率（曲线下面积0.82；95% CI，0.76-0.87）。
> 
> 结论：阳性CLT与重症患者再次插管风险的增加独立相关。当CLT结果与临床风险因素结合时，预测准确性进一步提高。这些发现提示，应在拔管决策中纳入CLT，尤其对于具有拔管后气道并发症高风险的患者。

### 第二部分 AI 大师评价

该研究旨在探讨拔管前袖囊漏气试验结果与再次插管风险之间的关系，基于742例重症患者的大样本回顾性数据。研究采用多变量逻辑回归分析，发现阳性CLT是再次插管的独立预测因素，且与多种临床危险因素联合后可显著提升预测准确度。其创新在于定量化漏气指标并整合多维风险评估模型，具有较高的临床指导意义。但研究为单中心回顾性设计，可能受样本选择偏倚所限，仍需前瞻性验证。

---

## 31. 长效型DNase I（PRX-119）静脉给药在小鼠多病原腹腔性脓毒症模型中的作用研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40705350)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 40705350
**DOI：** 10.1097/SHK.0000000000002666

### 第一部分 原文与翻译

**英文原标题：** Intravenous Delivery of Long-Acting Dnase I (PRX-119) In a Murine Model of Polymicrobial Abdominal Sepsis.

> **英文摘要：**
> OBJECTIVE: Sepsis is a life-threatening complication of infection in which a dysregulated host response precipitates multiorgan dysfunction. Neutrophil extracellular traps contribute to infection-induced immunothrombosis by releasing cell-free DNA (cfDNA), which provides a prothrombotic scaffold for blood clots. Although DNase I has therapeutic promise due to its ability to degrade cfDNA, its short plasma half-life (2 to 4 h) may necessitate multiple daily injections, potentially posing challenges for clinical use. This study investigates the efficacy of i.v. administration of PRX-119, a PEGylated recombinant human DNase I with an extended half-life of ~12 h.
> 
> METHODS: Sepsis was induced in C57Bl/6 mice (10-12 weeks old) using the cecal ligation and puncture (CLP) model. The efficacy of i.v. PRX-119 (1 mg/kg) was tested in 72-h and 7-day survival studies, including clinically relevant supportive therapies (antibiotics, fluid resuscitation). We measured plasma levels of cfDNA, IL-6, IL-10, and thrombin-antithrombin (TAT) complexes. We assessed physiological parameters, bacterial burden, lung myeloperoxidase, and organ injury/function.
> 
> RESULTS: Using both sexes, a single dose of PRX-119 (at T  = 8 h) or two doses (at T  = 4 and 24 h) improved survival at 72 h. Using male mice, we observed that three doses (at T  = 4, 20, and 36 post-CLP) provided a sustained protective effect at 7 days post-CLP. PRX-119 treatment reduced cfDNA, IL-6, TAT, lung myeloperoxidase, and bacterial load. PRX-119 treatment also reduced organ injury.
> 
> CONCLUSIONS: Intravenous delivery of PRX-119 improved survival and reduced immunothrombosis and organ injury, without the need for frequent injections.

> **中文摘要：**
> 目的：脓毒症是感染导致的危及生命的并发症，其特征为宿主失调的免疫反应引发多器官功能障碍。中性粒细胞胞外陷阱通过释放细胞外游离DNA（cfDNA），为血栓形成提供促凝支架，从而促进感染诱导的免疫性血栓形成。尽管DNase I可降解cfDNA，具有潜在的治疗前景，但其血浆半衰期较短（2至4小时），可能需要每日多次注射，从而对临床应用带来挑战。本研究旨在评估PEG化重组人DNase I（PRX-119）静脉给药（半衰期约12小时）的疗效。
> 
> 方法：采用盲肠结扎穿刺（CLP）方法在10至12周龄C57Bl/6小鼠中诱导脓毒症。对接受静脉注射PRX-119（1 mg/kg）的小鼠进行72小时及7天生存率研究，并结合临床相关的支持治疗（抗生素、液体复苏）。检测血浆中cfDNA、IL-6、IL-10及凝血酶-抗凝血酶复合物（TAT）的水平，评估生理参数、细菌负荷、肺髓过氧化物酶及器官损伤/功能。
> 
> 结果：在雌雄小鼠中，无论单次给药（T=8小时）或两次给药（T=4和24小时），PRX-119均显著改善72小时生存率。在雄性小鼠中，三次给药（CLP后T=4、20及36小时）在CLP后7天仍表现出持续的保护作用。PRX-119治疗可降低cfDNA、IL-6、TAT、肺髓过氧化物酶及细菌负荷水平，同时减轻器官损伤。
> 
> 结论：PRX-119静脉给药可在无需频繁注射的情况下改善生存率，减轻免疫性血栓形成和器官损伤。

### 第二部分 AI 大师评价

本研究旨在评估延长半衰期的PEG化DNase I（PRX-119）在小鼠多病原脓毒症模型中的治疗潜力。研究设计严谨，采用CLP模型并结合临床支持治疗，提高了实验的临床相关性。结果显示，PRX-119通过降低cfDNA与炎症、凝血及感染指标，有效改善了生存率与多器官损伤。创新之处在于利用药物修饰技术显著延长DNase I体内作用时间，减少给药频次。局限性在于仍需进一步验证其在大型动物及人体中的药代动力学与安全性。

---

## 32. 血小板计数、丙氨酸氨基转移酶和纤维蛋白原在鉴别不完全川崎病与败血症中的诊断价值

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40663481)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 40663481
**DOI：** 10.1097/SHK.0000000000002647

### 第一部分 原文与翻译

**英文原标题：** Diagnostic Value of Platelet Count, Alanine Aminotransferase, and Fibrinogen in Differentiating Incomplete Kawasaki Disease from Sepsis.

> **英文摘要：**
> OBJECTIVE: The aim of this study is to compare laboratory parameters between incomplete Kawasaki disease (IKD) and sepsis, and to evaluate the predictive value of common laboratory parameters in distinguishing IKD from sepsis.
> 
> METHODS: A retrospective analysis was conducted on medical records of patients diagnosed with Kawasaki disease or sepsis between January 2021 and December 2023. A total of 207 cases of IKD and 315 cases of sepsis were included in this study. Clinical data were analyzed to identify intergroup differences.
> 
> RESULTS: Significant intergroup differences ( P  < 0.05) were observed in blood platelet (PLT) count, procalcitonin, aspartate aminotransferase, alanine aminotransferase (ALT), urea nitrogen, creatinine, C-reactive protein, fibrinogen (Fib), and D-dimer levels. Markers with statistically significant variations relevant to the diagnosis of IKD were identified using binary logistic regression analysis. Receiver operating characteristic curve analysis demonstrated areas under the curve of 0.771 for PLT, 0.800 for ALT, and 0.755 for Fib. A combined assessment of these markers resulted in improved sensitivity and specificity.
> 
> CONCLUSION: PLT, ALT, and Fib can serve as laboratory markers for distinguishing IKD from sepsis and offer diagnostic reference value. Their combined assessment may improve the predictive accuracy for IKD.

> **中文摘要：**
> 目的：本研究旨在比较不完全川崎病（IKD）与败血症患者的实验室指标，并评估常见实验室参数在区分IKD与败血症中的预测价值。
> 
> 方法：对2021年1月至2023年12月期间诊断为川崎病或败血症的患者病历进行回顾性分析。本研究共纳入207例IKD患者和315例败血症患者。通过分析临床数据以识别组间差异。
> 
> 结果：在血小板（PLT）计数、降钙素原、天冬氨酸氨基转移酶、丙氨酸氨基转移酶（ALT）、尿素氮、肌酐、C反应蛋白、纤维蛋白原（Fib）及D-二聚体水平方面，组间差异具有统计学意义（P < 0.05）。通过二元Logistic回归分析筛选出与IKD诊断相关的显著差异性标志物。受试者工作特征曲线（ROC）分析显示，PLT、ALT及Fib的曲线下面积分别为0.771、0.800和0.755。联合评估这些指标可提高诊断的敏感性和特异性。
> 
> 结论：PLT、ALT及Fib可作为区分IKD与败血症的实验室标志物，具有一定的诊断参考价值。其联合评估可提高IKD的预测准确性。

### 第二部分 AI 大师评价

本研究聚焦于不完全川崎病与败血症在实验室指标上的差异，采用回顾性分析方法评估血小板、ALT及纤维蛋白原的诊断效能。研究发现这些指标均具有较高的区分能力，联合分析能显著提升敏感性与特异性。工作特色在于将多指标联合建模用于临床鉴别诊断，为提高儿科感染性疾病的诊断准确性提供了新思路。然而，其局限性在于回顾性设计和单中心研究，仍需前瞻性验证。

---

速递结束，祝您工作愉快！